BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GJ, Mcpherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology 2016;32:1263-82. [DOI: 10.1016/j.cjca.2016.07.510] [Cited by in Crossref: 563] [Cited by in F6Publishing: 494] [Article Influence: 93.8] [Reference Citation Analysis]
Number Citing Articles
1 Johnston IS, Miles B, Soos B, Garies S, Perez G, Queenan JA, Drummond N, Singer A. A cross-sectional study evaluating cardiovascular risk and statin prescribing in the Canadian Primary Care Sentinel Surveillance Network database. BMC Prim Care 2022;23:128. [DOI: 10.1186/s12875-022-01735-6] [Reference Citation Analysis]
2 Dubois E, Ducharme N, Lalonde D, Rysdale L. Undergraduate Medical Students’ Perceptions of Nutrition Education at the Northern Ontario School of Medicine. Canadian Journal of Dietetic Practice and Research 2022. [DOI: 10.3148/cjdpr-2022-025] [Reference Citation Analysis]
3 Li W, Bai W, Miao C, Chen S, Zhang X, Fan Y, Li X, Wu S, Liu X, Hong J. Joint effects of carotid plaques and renal impairment on the risk of cardiovascular disease and all-cause death in a community-based population: The Kailuan cohort study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.943718] [Reference Citation Analysis]
4 Zhang J, Tang Z, Jiang J, Huang S, Zeng H, Gu J, Wang C, Zhang H. Fasting and non-fasting lipoproteins and apolipoproteins for long-term outcome prediction in Chinese patients with coronary heart disease:a prospective observational study.. [DOI: 10.21203/rs.3.rs-2218224/v1] [Reference Citation Analysis]
5 Helk O, Böck A, Stefanutti C, Widhalm K. Lp(a) does not affect intima media thickness in hypercholesterolemic children –a retrospective cross sectional study. Atherosclerosis Plus 2022. [DOI: 10.1016/j.athplu.2022.11.001] [Reference Citation Analysis]
6 Li J, Ma C, Zhao D, Yan X, Li J, Ma C, Zhao D, Yan X, Ye P, Chen H, Li Y, Yuan Z, Zhang R, Zhao S, Lu G, Liang C, Dong Y, Chen Z, Peng D, Tang Y, Wang F, Zhou Z, Sun Y, Liu J, Guo Y, Yuan H, Wu N, Zhu Y. Lipoprotein(a) and Cardiovascular Disease in Chinese Population. JACC: Asia 2022;2:653-665. [DOI: 10.1016/j.jacasi.2022.08.015] [Reference Citation Analysis]
7 Zhao Z, Wang H, Hou Q, Zhou Y, Zhang Y. Non-traditional lipid parameters as potential predictors of carotid plaque vulnerability and stenosis in patients with acute ischemic stroke. Neurol Sci 2022. [DOI: 10.1007/s10072-022-06472-3] [Reference Citation Analysis]
8 Chung R, Xu Z, Arnold M, Ip S, Harrison H, Barrett J, Pennells L, Kim LG, Diangelantonio E, Paige E, Ritchie SC, Inouye M, Usher-smith JA, Wood AM. Using polygenic risk scores for prioritising individuals at greatest need of a CVD risk assessment.. [DOI: 10.1101/2022.10.20.22281120] [Reference Citation Analysis]
9 Dawson DR, Bar Y, Ajwani F, Rotenberg S, Atlas B, Ricupero M, Greewood C, Parrott MD. Combining elements of the CO-OP Approach™ with education to promote healthy eating among older adults: A pilot study. Front Rehabilit Sci 2022;3. [DOI: 10.3389/fresc.2022.971300] [Reference Citation Analysis]
10 Shi H, Zhou J, Ma C, Ji F, Wu Y, Zhao Y, Qian J, Wang X. Shexiang Baoxin Pill reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial. Front Cardiovasc Med 2022;9:1002400. [DOI: 10.3389/fcvm.2022.1002400] [Reference Citation Analysis]
11 Saharia GK, Nayak S, Mahajan PB, Mangaraj M. Exploring the Novelty in Lipid Profiling of Patients: A Non-fasting Approach from Eastern India. J Lab Physicians. [DOI: 10.1055/s-0042-1757410] [Reference Citation Analysis]
12 Bhat S, Elman D, Pyakurel A, Fleming K. The prevalence of documented cardiovascular-related pregnancy complications: cross-sectional study in an academic primary care centre. BJGP Open 2022. [DOI: 10.3399/bjgpo.2022.0070] [Reference Citation Analysis]
13 Guzman-Vilca WC, Quispe-Villegas GA, Carrillo-Larco RM. Predicted heart age profile across 41 countries: A cross-sectional study of nationally representative surveys in six world regions. EClinicalMedicine 2022;52:101688. [PMID: 36313150 DOI: 10.1016/j.eclinm.2022.101688] [Reference Citation Analysis]
14 França V, Gomes ÉIL, de Campos EVS, Zago VHS, Nunes VS, de Faria EC. Relationship between lipoprotein (a) and subclinical carotid atherosclerosis in asymptomatic individuals. Clinics (Sao Paulo) 2022;77:100107. [PMID: 36179527 DOI: 10.1016/j.clinsp.2022.100107] [Reference Citation Analysis]
15 Qi X, Chiavaroli L, Lee D, Ayoub-charette S, Khan TA, Au-yeung F, Ahmed A, Cheung A, Liu Q, Blanco Mejia S, Choo VL, de Souza RJ, Wolever TMS, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL. Effect of Important Food Sources of Fructose-Containing Sugars on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Nutrients 2022;14:3986. [DOI: 10.3390/nu14193986] [Reference Citation Analysis]
16 Cui C, Ye T, Cheng L, Tong L, Tong L, Zhang Z, Cai L. Lipoprotein a Combined with Fibrinogen as an Independent Predictor of Long-Term Prognosis in Patients with Acute Coronary Syndrome: A Multi-Center Retrospective Study. JCDD 2022;9:322. [DOI: 10.3390/jcdd9100322] [Reference Citation Analysis]
17 Chun H, Oh J, Doo M. The Risk of Cardiovascular Disease According to Chewing Status Could Be Modulated by Healthy Diet in Middle-Aged Koreans. Nutrients 2022;14:3849. [PMID: 36145225 DOI: 10.3390/nu14183849] [Reference Citation Analysis]
18 Sena C, Ohene-Adjei M, Deng S, Patibandla N, May B, de Ferranti SD, Starc TJ, Thaker VV. Lack of age-appropriate reference intervals causing potentially missed alerts in clinical reports of dyslipidemia. J Pediatr 2022:S0022-3476(22)00726-0. [PMID: 36115623 DOI: 10.1016/j.jpeds.2022.08.017] [Reference Citation Analysis]
19 Johri AM, Singh KV, Mantella LE, Saba L, Sharma A, Laird JR, Utkarsh K, Singh IM, Gupta S, Kalra MS, Suri JS. Deep learning artificial intelligence framework for multiclass coronary artery disease prediction using combination of conventional risk factors, carotid ultrasound, and intraplaque neovascularization. Comput Biol Med 2022;150:106018. [PMID: 36174330 DOI: 10.1016/j.compbiomed.2022.106018] [Reference Citation Analysis]
20 Massara P, Zurbau A, Glenn AJ, Chiavaroli L, Khan TA, Viguiliouk E, Mejia SB, Comelli EM, Chen V, Schwab U, Risérus U, Uusitupa M, Aas AM, Hermansen K, Thorsdottir I, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CWC, Sievenpiper JL. Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials. Diabetologia 2022. [PMID: 36008559 DOI: 10.1007/s00125-022-05760-z] [Reference Citation Analysis]
21 Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022:S1933-2874(22)00244-6. [PMID: 36068139 DOI: 10.1016/j.jacl.2022.08.007] [Reference Citation Analysis]
22 Kganakga JT, Bester P, Ricci C, Botha-le Roux S, Cockeran M, Greeff M, Kruger IM. Prognostic values of modifiable risk factors for cardiovascular events in South African health promotion. PLoS ONE 2022;17:e0271169. [DOI: 10.1371/journal.pone.0271169] [Reference Citation Analysis]
23 Jovanovski E, Nguyen M, Kurahashi Y, Komishon A, Li D, Hoang Vi Thanh H, Khayyat R, Jenkins AL, Khan TA, Zurbau A, Sievenpiper J, Vuksan V. Are all fibres created equal with respect to lipid lowering? Comparing the effect of viscous dietary fibre to non-viscous fibre from cereal sources: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2022. [DOI: 10.1017/s0007114522002355] [Reference Citation Analysis]
24 Bekele DM, Goshu DY, Yalew AW, Higgins MK, Gary RA. Low Subjective Cardiovascular Disease Risk Perceptions among Hypertensive Patients in Addis Ababa, Ethiopia. IBPC 2022;Volume 15:81-96. [DOI: 10.2147/ibpc.s370838] [Reference Citation Analysis]
25 Malik AO, Chen H, Tang F, Chan PS, Cooper A, Gomes MB, Hejjaji V, Ji L, Khunti K, Kosiborod M, Nicolucci A, Peri-Okonny PA, Shestakova MV, Vora J, Watada H, Arnold SV. Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER Study. Indian Heart J 2022:S0019-4832(22)00112-2. [PMID: 35926587 DOI: 10.1016/j.ihj.2022.07.008] [Reference Citation Analysis]
26 Noronha JC, Kendall CW, Sievenpiper JL. Meal Replacements for Weight-Related Complications in Type 2 Diabetes: What Is the State of the Evidence? Front Endocrinol 2022;13:875535. [DOI: 10.3389/fendo.2022.875535] [Reference Citation Analysis]
27 Krzesińska A, Kłosowska A, Sałaga-zaleska K, Ćwiklińska A, Mickiewicz A, Chyła G, Wierzba J, Jankowski M, Kuchta A. Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome. JCM 2022;11:4356. [DOI: 10.3390/jcm11154356] [Reference Citation Analysis]
28 Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Review of Cardiovascular Therapy. [DOI: 10.1080/14779072.2022.2103541] [Reference Citation Analysis]
29 Murphy MSQ, Benton SJ, Cox B, Nerenberg K, Mccomb S, Krishnan L, Weeratna RD, Paré J, Dingwall-harvey ALJ, Bainbridge SA, Gruslin A, Gaudet LM. Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after Preeclampsia. JCM 2022;11:4185. [DOI: 10.3390/jcm11144185] [Reference Citation Analysis]
30 Nikhanj A, Bautista J, Siddiqi ZA, Phan CL, Oudit GY. Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations. J Cardiovasc Dev Dis 2022;9:221. [PMID: 35877583 DOI: 10.3390/jcdd9070221] [Reference Citation Analysis]
31 Loh WJ, Watts GF. The Inherited Hypercholesterolemias. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.02.006] [Reference Citation Analysis]
32 Gomez-Delgado F, Romero-Cabrera JL, Perez-Martinez P. Diet and vascular risk. Curr Opin Cardiol 2022;37:343-9. [PMID: 35731680 DOI: 10.1097/HCO.0000000000000960] [Reference Citation Analysis]
33 Pezel T, Sanguineti F, Garot P, Unterseeh T, Champagne S, Toupin S, Morisset S, Hovasse T, Faradji A, Ah-Sing T, Nicol M, Hamzi L, Dillinger JG, Henry P, Bousson V, Garot J. Machine-Learning Score Using Stress CMR for Death Prediction in Patients With Suspected or Known CAD. JACC Cardiovasc Imaging 2022:S1936-878X(22)00341-2. [PMID: 35842360 DOI: 10.1016/j.jcmg.2022.05.007] [Reference Citation Analysis]
34 Kalenga CZ, Hay JL, Boreskie KF, Duhamel TA, Macrae JM, Metcalfe A, Nerenberg KA, Robert M, Ahmed SB. The Association Between Route of Post-menopausal Estrogen Administration and Blood Pressure and Arterial Stiffness in Community-Dwelling Women. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.913609] [Reference Citation Analysis]
35 Chen D, Tang J, Gong T, Mu L, Li J, Yu P, Wang H, Bu X, Mu L, Mei Y. Short-term effects of modest salt reduction combined with DASH diet on changing salt eating habits in hypertensive patients with type II diabetes. Clin Exp Hypertens 2022;:1-9. [PMID: 35611762 DOI: 10.1080/10641963.2022.2079666] [Reference Citation Analysis]
36 Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, Zhang R, Wang H, Cai Z, Feng L, Dou K. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention? J Am Heart Assoc 2022;11:e023578. [PMID: 35475627 DOI: 10.1161/JAHA.121.023578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Mohammadi-Shemirani P, Chong M, Narula S, Perrot N, Conen D, Roberts JD, Thériault S, Bossé Y, Lanktree MB, Pigeyre M, Paré G. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol 2022;79:1579-90. [PMID: 35450575 DOI: 10.1016/j.jacc.2022.02.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
38 Liu Q, Yu Y, Xi R, Li J, Lai R, Wang T, Fan Y, Zhang Z, Xu H, Ju J. Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.877140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Florian M, Li B, Patry D, Truong J, Caldwell D, Coughlan MC, Woodworth R, Yan J, Chen Q, Petrov I, Mahemuti L, Lalande M, Li N, Chan LHM, Willmore WG, Jin X. Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study. Cardiovasc Toxicol. [DOI: 10.1007/s12012-022-09738-6] [Reference Citation Analysis]
40 Lucchi T. Lipid management. Pathy's Principles and Practice of Geriatric Medicine 2022. [DOI: 10.1002/9781119484288.ch31] [Reference Citation Analysis]
41 Ahmadian F, Razmpoosh E, Ejtahed HS, Javadi M, Mirmiran P, Azizi F. Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial. Diabetol Metab Syndr 2022;14:52. [PMID: 35418091 DOI: 10.1186/s13098-022-00822-z] [Reference Citation Analysis]
42 White-al Habeeb NM, Higgins V, Venner AA, Bailey D, Beriault DR, Collier C, Adeli K. Canadian Society of Clinical Chemists (CSCC) Harmonized Clinical Laboratory Lipid Reporting Recommendations based on 2021 Canadian Cardiovascular Society Lipid Guidelines. Canadian Journal of Cardiology 2022. [DOI: 10.1016/j.cjca.2022.03.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Bittman J, Thomson CJ, Lyall LA, Alexis SL, Lyall ET, Cannatella SL, Ebtia M, Freedman BK, Alizadeh-pasdar N, Ledrew JM, Orenstein Lyall TL. Effect of an Exercise and Nutrition Program on Quality of Life in Patient with Atrial Fibrillation: The Atrial Fibrillation Lifestyle Project (ALP). CJC Open 2022. [DOI: 10.1016/j.cjco.2022.04.004] [Reference Citation Analysis]
44 Putra RP, Rochmawati ID, Prima DA. The impact of mobile application: "Friends of Heart" in knowledge and compliance of patients with coronary heart disease. PE. [DOI: 10.46542/pe.2022.222.3640] [Reference Citation Analysis]
45 Suri JS, Bhagawati M, Paul S, Protogerou AD, Sfikakis PP, Kitas GD, Khanna NN, Ruzsa Z, Sharma AM, Saxena S, Faa G, Laird JR, Johri AM, Kalra MK, Paraskevas KI, Saba L. A Powerful Paradigm for Cardiovascular Risk Stratification Using Multiclass, Multi-Label, and Ensemble-Based Machine Learning Paradigms: A Narrative Review. Diagnostics 2022;12:722. [DOI: 10.3390/diagnostics12030722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Glenn A, Kavanagh M, Bockus‐thorne L, Mcneill L, Melina V, Jenkins D, Grant S. Medical nutrition therapy for chronic pain management. Clinical Pain Management 2022. [DOI: 10.1002/9781119701170.ch14] [Reference Citation Analysis]
47 Cho GJ, Kim J, Kim JY, Han SW, Lee SB, Oh MJ, Kim SJ, Shin JE. Adverse Pregnancy Outcomes and Maternal Chronic Diseases in the Future: A Cross-Sectional Study Using KoGES-HEXA Data. J Clin Med 2022;11:1457. [PMID: 35268548 DOI: 10.3390/jcm11051457] [Reference Citation Analysis]
48 Husain MJ, Spencer G, Nugent R, Kostova D, Richter P. The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review. gh 2022;17:18. [DOI: 10.5334/gh.1097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Tian S, Bi M, Bi Y, Che X, Liu Y. A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study. JMIR Med Inform 2022;10:e33026. [PMID: 35234651 DOI: 10.2196/33026] [Reference Citation Analysis]
50 Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, Pandey AS, Reiner M, Beltran J, Oliveira T, Mackinnon ES. Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. CJC Open 2022. [DOI: 10.1016/j.cjco.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Catapano AL, Daccord M, Damato E, Humphries SE, Neely RDG, Nordestgaard BG, Pistollato M, Steinhagen-thiessen E. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, Tonelli M. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol 2022;4:85-94. [PMID: 35492824 DOI: 10.1016/j.jaccao.2022.01.100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
53 Zhang Y, Zhao X, Ding X, Chen H, Li H, Li W. Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022;:33197221075861. [PMID: 35191328 DOI: 10.1177/00033197221075861] [Reference Citation Analysis]
54 Keathley J, Garneau V, Marcil V, Mutch DM, Robitaille J, Rudkowska I, Sofian G, Desroches S, Vohl M. Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids. Front Nutr 2022;8:768474. [DOI: 10.3389/fnut.2021.768474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Merćep I, Friščić N, Strikić D, Reiner Ž, Tomlinson B. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics 2022;2022:1-6. [DOI: 10.1155/2022/8129513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
56 Kopecky SL, Alias S, Klodas E, Jones PJH. Reduction in Serum LDL Cholesterol Using a Nutrient Compendium in Hyperlipidemic Adults Unable or Unwilling to Use Statin Therapy: A Double-Blind Randomized Crossover Clinical Trial. The Journal of Nutrition 2022. [DOI: 10.1093/jn/nxab375] [Reference Citation Analysis]
57 Wu Y, Xin J, Loehrer EA, Jiang X, Yuan Q, Christiani DC, Shi H, Liu L, Li S, Wang M, Chu H, Du M, Zhang Z. High-density lipoprotein, low-density lipoprotein and triglyceride levels and upper gastrointestinal cancers risk: a trans-ancestry Mendelian randomization study. Eur J Clin Nutr. [DOI: 10.1038/s41430-022-01078-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Mironova OI, Isaikina MA, Khasieva SA. Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskii arkhiv 2022;93:1533-8. [DOI: 10.26442/00403660.2021.12.201225] [Reference Citation Analysis]
59 Al-Karaghouli M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. BMJ Open Gastroenterol 2022;9:e000798. [PMID: 34992072 DOI: 10.1136/bmjgast-2021-000798] [Reference Citation Analysis]
60 Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and older. Archives of Gerontology and Geriatrics 2022. [DOI: 10.1016/j.archger.2022.104644] [Reference Citation Analysis]
61 Hooper AJ, Hegele RA, Burnett JR. Disorders of Lipoprotein Metabolism. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases 2022. [DOI: 10.1007/978-3-030-67727-5_53] [Reference Citation Analysis]
62 Waters H, Werstuck MM. Physical Activity and Nutrition in Chronic Kidney Disease. Psychonephrology 2022. [DOI: 10.1007/978-3-030-84740-1_19] [Reference Citation Analysis]
63 Simard T, Jung RG, Di Santo P, Harnett DT, Abdel-Razek O, Ramirez FD, Motazedian P, Parlow S, Labinaz A, Moreland R, Marbach J, Poulin A, Levi A, Majeed K, Boland P, Couture E, Sarathy K, Promislow S, Russo JJ, Chong AY, So D, Froeschl M, Dick A, Labinaz M, Le May M, Holmes DR Jr, Hibbert B. Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights From a Regionalized Dedicated Follow-Up Clinic. Mayo Clin Proc Innov Qual Outcomes 2021;5:1138-52. [PMID: 34934904 DOI: 10.1016/j.mayocpiqo.2021.09.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Cui K, Wang H, Yin D, Zhu C, Song W, Wang H, Jia L, Zhang D, Song C, Feng L, Dou K. Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations. Front Cardiovasc Med 2021;8. [DOI: 10.3389/fcvm.2021.807925] [Reference Citation Analysis]
65 Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021;:109177. [PMID: 34923023 DOI: 10.1016/j.diabres.2021.109177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2021;341:20-6. [PMID: 34959205 DOI: 10.1016/j.atherosclerosis.2021.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kavanagh ME, Chiavaroli L, Glenn AJ, Heijmans G, Grant SM, Chow C, Josse RG, Malik VS, Watson W, Lofters A, Holmes C, Rackal J, Srichaikul K, Sherifali D, Snelgrove-clarke E, Udell JA, Juni P, Booth GL, Farkouh ME, Leiter LA, Kendall CW, Jenkins DJ, Sievenpiper JL. A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study (Preprint).. [DOI: 10.2196/preprints.34704] [Reference Citation Analysis]
68 Kavanagh ME, Chiavaroli L, Glenn AJ, Heijmans G, Grant SM, Chow C, Josse RG, Malik VS, Watson W, Lofters A, Holmes C, Rackal J, Srichaikul K, Sherifali D, Snelgrove-clarke E, Udell JA, Juni P, Booth GL, Farkouh M, Leiter LA, Kendall CW, Jenkins DJ, Sievenpiper JL. Quality improvement and usability testing of the PortfolioDiet.app, a web-based health application to translate nutrition therapy for cardiovascular risk reduction in primary care (Preprint). JMIR Human Factors. [DOI: 10.2196/34704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Yang K, Liu W. Triglyceride and Glucose Index and Sex Differences in Relation to Major Adverse Cardiovascular Events in Hypertensive Patients Without Diabetes. Front Endocrinol (Lausanne) 2021;12:761397. [PMID: 34803922 DOI: 10.3389/fendo.2021.761397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Applications of Microbial Fermentation to Food Products, Chemicals and Pharmaceuticals. Advanced Fermentation and Cell Technology 2021. [DOI: 10.1002/9781119042792.part2] [Reference Citation Analysis]
71 Granger MJ, Eck PK, Vazquez-Vidal I, Shamloo M, House JD, Mackay DS. Genosets for APOE and CYP7A1-rs3808607 variants do not predict low-density lipoprotein cholesterol lowering upon intervention with plant sterols in a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2021:nqab378. [PMID: 34791009 DOI: 10.1093/ajcn/nqab378] [Reference Citation Analysis]
72 Barry AR, Babadagli HE, Boswell R, Chen JW, Dawson EL, Lopaschuk DG, McMillan CL, Nguyen BV, Omar MA, Pollmann DM, Zhou JS, Ackman ML. Review of the top 5 cardiology studies of 2019-20. Can Pharm J (Ott) 2021;154:388-93. [PMID: 34777649 DOI: 10.1177/17151635211029328] [Reference Citation Analysis]
73 Kexin W, Yaodong D, Wen G, Rui W, Jiaxin Y, Xiaoli L, Hua S, Hailong G. Association of Increased Remnant Cholesterol and the Risk of Coronary Artery Disease: A Retrospective Study. Front Cardiovasc Med 2021;8:740596. [PMID: 34778402 DOI: 10.3389/fcvm.2021.740596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
74 Evans M, Lewis ED, Crowley DC, Zeng A, Struve J, Guthrie N. A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus® NotoGinseng Extract on Cholesterol and Blood Pressure. CNT 2021;2:301-311. [DOI: 10.2174/2665978602666210714131146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Escobedo A, Rivera-León EA, Luévano-Contreras C, Urías-Silvas JE, Luna-Vital DA, Morales-Hernández N, Mojica L. Common Bean Baked Snack Consumption Reduces Apolipoprotein B-100 Levels: A Randomized Crossover Trial. Nutrients 2021;13:3898. [PMID: 34836152 DOI: 10.3390/nu13113898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, Saraiva JFK, Chacra APM, Martinez TLR, Bahia LR, Fonseca FAH, Faludi AA, Sposito AC, Chagas ACP, Jannes CE, Amaral CK, Araújo DB, Cintra DE, Coutinho EDR, Cesena F, Xavier HT, Mota ICP, Giuliano ICB, Faria Neto JR, Kato JT, Bertolami MC, Miname MH, Castelo MHCG, Lavrador MSF, Machado RM, Souza PG, Alves RJ, Machado VA, Salgado Filho W. Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. Arq Bras Cardiol 2021;117:782-844. [PMID: 34709306 DOI: 10.36660/abc.20210788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Higgins V, Leiter LA, Delaney SR, Beriault DR. Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up? Clin Biochem 2022;99:60-8. [PMID: 34656564 DOI: 10.1016/j.clinbiochem.2021.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
78 Radkhah N, Shabbidar S, Zarezadeh M, Safaeiyan A, Barzegar A. Effects of vitamin D supplementation on apolipoprotein A1 and B100 levels in adults: Systematic review and meta-analysis of controlled clinical trials. J Cardiovasc Thorac Res 2021;13:190-7. [PMID: 34630965 DOI: 10.34172/jcvtr.2021.21] [Reference Citation Analysis]
79 Donald M, Smekal MD, Elliott MJ, McBrien K, Weaver RG, Manns BJ, Tonelli M, Bello A, Straus SE, Scott-Douglas N, Jindal K, Hemmelgarn BR. Online clinical pathway for chronic kidney disease management in primary care: a retrospective cohort study. BMC Nephrol 2021;22:332. [PMID: 34615462 DOI: 10.1186/s12882-021-02533-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Silveira EA, Noll PRES, Mohammadifard N, Rodrigues APS, Sarrafzadegan N, de Oliveira C. Which Diets Are Effective in Reducing Cardiovascular and Cancer Risk in Women with Obesity? An Integrative Review. Nutrients 2021;13:3504. [PMID: 34684505 DOI: 10.3390/nu13103504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
81 Gómez-sánchez M, Gómez-sánchez L, Patino-alonso MC, Alonso-domínguez R, Sánchez-aguadero N, Recio-rodríguez JI, González-sánchez J, García-ortiz L, Gómez-marcos MA. Relación del envejecimiento vascular saludable con los estilos de vida y el síndrome metabólico en población general española. Estudio EVA. Revista Española de Cardiología 2021;74:854-61. [DOI: 10.1016/j.recesp.2020.06.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Mackinnon ES, Goeree R, Goodman SG, Rogoza RM, Packalen M, Pericleous L, Motsepe-ditshego P, Oh P. Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018. CJC Open 2021. [DOI: 10.1016/j.cjco.2021.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Xu Z, Arnold M, Stevens D, Kaptoge S, Pennells L, Sweeting MJ, Barrett J, Di Angelantonio E, Wood AM. Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. Am J Epidemiol 2021;190:2000-14. [PMID: 33595074 DOI: 10.1093/aje/kwab031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. Am J Nephrol 2021;52:693-701. [PMID: 34569479 DOI: 10.1159/000518456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Hiersch L, Ray JG, Barrett J, Berger H, Geary M, McDonald SD, Diong C, Gandhi S, Guan J, Murray-Davis B, Melamed N; DOH-NET (Diabetes, Obesity and Hypertension in Pregnancy Research Network). Maternal cardiovascular disease after twin pregnancies complicated by hypertensive disorders of pregnancy: a population-based cohort study. CMAJ 2021;193:E1448-58. [PMID: 34544783 DOI: 10.1503/cmaj.202837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
86 Barclay AW, Augustin LSA, Brighenti F, Delport E, Henry CJ, Sievenpiper JL, Usic K, Yuexin Y, Zurbau A, Wolever TMS, Astrup A, Bulló M, Buyken A, Ceriello A, Ellis PR, Vanginkel MA, Kendall CWC, La Vecchia C, Livesey G, Poli A, Riccardi G, Salas-Salvadó J, Trichopoulou A, Bhaskaran K, Jenkins DJA, Willett WC, Brand-Miller JC. Dietary Glycaemic Index Labelling: A Global Perspective. Nutrients 2021;13:3244. [PMID: 34579120 DOI: 10.3390/nu13093244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
87 Zhang SL, Du X, Xu J, Xiang QY, Liu L. Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants. Cardiovasc Diagn Ther 2021;11:991-1001. [PMID: 34527522 DOI: 10.21037/cdt-20-1012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Nishi SK, Viguiliouk E, Blanco Mejia S, Kendall CWC, Bazinet RP, Hanley AJ, Comelli EM, Salas Salvadó J, Jenkins DJA, Sievenpiper JL. Are fatty nuts a weighty concern? A systematic review and meta-analysis and dose-response meta-regression of prospective cohorts and randomized controlled trials. Obes Rev 2021;22:e13330. [PMID: 34494363 DOI: 10.1111/obr.13330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
89 Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary Lipids and Dyslipidemia in Chronic Kidney Disease. Nutrients 2021;13:3138. [PMID: 34579015 DOI: 10.3390/nu13093138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
90 Berglund L, Kim K, Zhang W, Prakash N, Truax K, Anuurad E, Enkhmaa B. Lp(a)-Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure. J Am Heart Assoc 2021;10:e020158. [PMID: 34431330 DOI: 10.1161/JAHA.120.020158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Saeed A, Zhu J, Thoma F, Marroquin O, Aiyer A, Agarwala A, Virani SS, Gulati M, Lee JS, Reis S, Saba S, Ballantyne C, Mulukutla S. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes 2021;14:e007485. [PMID: 34455825 DOI: 10.1161/CIRCOUTCOMES.120.007485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
92 Zhu LY, Wen XY, Xiang QY, Guo LL, Xu J, Zhao SP, Liu L. Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease. Front Cardiovasc Med 2021;8:674446. [PMID: 34434972 DOI: 10.3389/fcvm.2021.674446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Glenn AJ, Boucher BA, Kavcic CC, Khan TA, Paquette M, Kendall CWC, Hanley AJ, Jenkins DJA, Sievenpiper JL. Development of a Portfolio Diet Score and Its Concurrent and Predictive Validity Assessed by a Food Frequency Questionnaire. Nutrients 2021;13:2850. [PMID: 34445009 DOI: 10.3390/nu13082850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Sunner SS, Welsh RC, Bainey KR. Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. CJC Open 2021;3:936-49. [PMID: 34401701 DOI: 10.1016/j.cjco.2021.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
95 Tian S, Bi M, Bi Y, Che X, Liu Y. A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study (Preprint).. [DOI: 10.2196/preprints.33026] [Reference Citation Analysis]
96 Parthymos I, Kostapanos MS, Mikhailidis DP, Florentin M. Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. Eur J Prev Cardiol 2021:zwab052. [PMID: 34389859 DOI: 10.1093/eurjpc/zwab052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
97 Chang HH, Lan YC, Chung SD, Chien CT. Sweet Potato Leaf Feeding Decreases Cholesterol, Oxidative Stress and Thrombosis Formation in Syrian Hamsters with a High-Cholesterol Diet. Life (Basel) 2021;11:802. [PMID: 34440546 DOI: 10.3390/life11080802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Glenn AJ, Lo K, Jenkins DJA, Boucher BA, Hanley AJ, Kendall CWC, Manson JE, Vitolins MZ, Snetselaar LG, Liu S, Sievenpiper JL. Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women's Health Initiative Prospective Cohort Study. J Am Heart Assoc 2021;10:e021515. [PMID: 34346245 DOI: 10.1161/JAHA.121.021515] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
99 Chiavaroli L, Lee D, Ahmed A, Cheung A, Khan TA, Blanco S, Mejia, Mirrahimi A, Jenkins DJA, Livesey G, Wolever TMS, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CWC, Sievenpiper JL. Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2021;374:n1651. [PMID: 34348965 DOI: 10.1136/bmj.n1651] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
100 Moutawakilou G, Corinne TT, Tarik S, Gilbert D, Stanislas Z. Serum lipid profile based on the prandial state among adult subjects. Afr J Biochem Res 2021;15:15-21. [DOI: 10.5897/ajbr2021.1118] [Reference Citation Analysis]
101 Marcotte-Chénard A, Tremblay D, Mony MM, Brochu M, Dionne IJ, Langlois MF, Mampuya W, Morais J, Tessier D, Riesco E. Low-volume walking HIIT: Efficient strategy to improve physical capacity and reduce the risk of cardiovascular disease in older women with type 2 diabetes. Diabetes Metab Syndr 2021;15:102233. [PMID: 34364301 DOI: 10.1016/j.dsx.2021.102233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
102 Barańska A, Błaszczuk A, Kanadys W, Baczewska B, Jędrych M, Wawryk-Gawda E, Polz-Dacewicz M. Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women as a Potential Prevention Factor in Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2021;13:2531. [PMID: 34444691 DOI: 10.3390/nu13082531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima JAC, Puri R, Nomura SO, Tsai MY, Wilkins JT, Ballantyne CM, Nicholls SJ, Jones SR, Elshazly MB. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J 2021:ehab432. [PMID: 34293083 DOI: 10.1093/eurheartj/ehab432] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 35.0] [Reference Citation Analysis]
104 Patel AP, Wang M, Kartoun U, Ng K, Khera AV. Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study. Circulation 2021;144:410-22. [PMID: 34247495 DOI: 10.1161/CIRCULATIONAHA.120.052430] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 23.0] [Reference Citation Analysis]
105 Langer A, Mancini GBJ, Tan M, Goodman SG, Ahooja V, Grégoire J, Lin PJ, Stone JA, Leiter LA. Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc 2021;10:e020126. [PMID: 34238023 DOI: 10.1161/JAHA.120.020126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Farukhi Z, Mora S. Nonfasting Lipids for All Patients? Clin Chem 2021;67:41-5. [PMID: 33221866 DOI: 10.1093/clinchem/hvaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
107 Nicholls SJ, Bubb KJ. The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All? Curr Cardiol Rep 2021;23:97. [PMID: 34196823 DOI: 10.1007/s11886-021-01528-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
108 Wu H, Sharaf M, Shalansky K, Zalunardo N. Evaluation of Statin Use and Prescribing in Patients with Chronic Kidney Disease Not Receiving Treatment with Kidney Transplant or Dialysis. Can J Hosp Pharm 2021;74:219-26. [PMID: 34248162 DOI: 10.4212/cjhp.v74i3.3149] [Reference Citation Analysis]
109 Hasan S, Naugler C, Decker J, Fung M, Morrin L, Campbell NRC, Anderson TJ. Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. Clin Biochem 2021:S0009-9120(21)00173-9. [PMID: 34197811 DOI: 10.1016/j.clinbiochem.2021.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mortensen MB, Blaha MJ. Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions. Curr Atheroscler Rep 2021;23:44. [PMID: 34146160 DOI: 10.1007/s11883-021-00943-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Vine D, Proctor E, Weaver O, Ghosh M, Maximova K, Proctor S. A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome. J Endocr Soc 2021;5:bvab114. [PMID: 34286169 DOI: 10.1210/jendso/bvab114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Saeed A, Kinoush S, Virani SS. Lipoprotein (a): Recent Updates on a Unique Lipoprotein. Curr Atheroscler Rep 2021;23:41. [PMID: 34146181 DOI: 10.1007/s11883-021-00940-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
113 Lin Q, Fu Y, Zang X, Liu Q, Liu L. The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease. Front Cardiovasc Med 2021;8:686234. [PMID: 34222380 DOI: 10.3389/fcvm.2021.686234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Yashima F, Hara M, Inohara T, Jinzaki M, Shimizu H, Fukuda K, Tanaka M, Yamamoto M, Watanabe Y, Naganuma T, Shirai S, Yamawaki M, Tada N, Yamanaka F, Mizutani K, Ueno H, Tabata M, Takagi K, Hayashida K; OCEAN-TAVI registry. Statin therapy for patients with aortic stenosis who underwent transcatheter aortic valve implantation: a report from a Japanese multicentre registry. BMJ Open 2021;11:e044319. [PMID: 34117043 DOI: 10.1136/bmjopen-2020-044319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Al Hamarneh YN, Okada H, Tsuyuki RT. Real-world implementation of diabetes management by pharmacists: The RXING Practice Tool. Can Pharm J (Ott) 2021;154:160-5. [PMID: 34104269 DOI: 10.1177/17151635211004964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Cartier LJ, Robin A, St-Cœur S, Lagacé M, Canales DD, Douville P. Impact of the 2016 Canadian Lipid Guidelines on Daily Practice at a Community Hospital. Can J Diabetes 2021:S1499-2671(21)00168-4. [PMID: 34340938 DOI: 10.1016/j.jcjd.2021.06.002] [Reference Citation Analysis]
117 Cho Y, Jeong Y, Seo DH, Ahn SH, Hong S, Suh YJ, Kim SH. Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. Atherosclerosis 2021;328:92-9. [PMID: 34126505 DOI: 10.1016/j.atherosclerosis.2021.05.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
118 El Hussein MT, Hakkola J. Management strategies for STE-ACS. Nurse Pract 2021;46:18-26. [PMID: 34004636 DOI: 10.1097/01.NPR.0000751820.32888.e0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Abamba Omwange K, Al Riza DF, Saito Y, Suzuki T, Ogawa Y, Shiraga K, Giametta F, Kondo N. Potential of front face fluorescence spectroscopy and fluorescence imaging in discriminating adulterated extra-virgin olive oil with virgin olive oil. Food Control 2021;124:107906. [DOI: 10.1016/j.foodcont.2021.107906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
120 Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med 2021;8:e000448. [PMID: 34045359 DOI: 10.1136/lupus-2020-000448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
121 Rose AV, Boreskie KF, Hay JL, Thompson L, Arora RC, Duhamel TA. Protocol for the WARM Hearts study: examining cardiovascular disease risk in middle-aged and older women - a prospective, observational cohort study. BMJ Open 2021;11:e044227. [PMID: 34035097 DOI: 10.1136/bmjopen-2020-044227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020;58:496-517. [PMID: 31855562 DOI: 10.1515/cclm-2019-1253] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 57.0] [Reference Citation Analysis]
123 Islam SU, Ahmed MB, Ahsan H, Lee YS. Recent Molecular Mechanisms and Beneficial Effects of Phytochemicals and Plant-Based Whole Foods in Reducing LDL-C and Preventing Cardiovascular Disease. Antioxidants (Basel) 2021;10:784. [PMID: 34063371 DOI: 10.3390/antiox10050784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
124 Mortensen MB, Nordestgaard BG. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. Eur Heart J 2020;41:3005-15. [PMID: 32227172 DOI: 10.1093/eurheartj/ehaa150] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
125 Migdalis IN, Papanas N, Ioannidis IM, Sotiropoulos AE, Raptis AE, Dimitriadis GD, On Behalf Of The Hellenic Diabetic Nephropathy Study Hdns. Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece. J Clin Med 2021;10:2104. [PMID: 34068380 DOI: 10.3390/jcm10102104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ 2021;373:n776. [PMID: 33947652 DOI: 10.1136/bmj.n776] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
127 Eraikhuemen N, Lazaridis D, Dutton MT. Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. Am J Cardiovasc Drugs 2021;21:255-65. [PMID: 32929693 DOI: 10.1007/s40256-020-00437-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Sang T, Cheng N, Dang A, Lv N, Zhang W, Li Y, Ji Y, Gu Y. Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. J Clin Lipidol 2021;15:466-76. [PMID: 34006456 DOI: 10.1016/j.jacl.2021.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
129 Goldenberg RM, Cheng AYY, Gilbert JD, Lonn EM, Pedersen SD, Verma S. The role of icosapent ethyl in cardiovascular risk reduction. Curr Opin Cardiol 2021;36:661-71. [PMID: 33929367 DOI: 10.1097/HCO.0000000000000873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Zhao Y, Liu L, Yang S, Liu G, Pan L, Gu C, Wang Y, Li D, Zhao R, Wu M. Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. Front Cardiovasc Med 2021;8:636947. [PMID: 33996937 DOI: 10.3389/fcvm.2021.636947] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
131 Ackman ML, Koshman S, Pearson GJ, Semchuk W, Shamiss Y, Thompson A, Warner T. Lipid therapy: A new whiteboard video for patient education. Can Pharm J (Ott) 2021;154:175-8. [PMID: 34104271 DOI: 10.1177/17151635211006166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Page MM, Watts GF. Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. Curr Opin Cardiol 2021;36:272-80. [PMID: 33741767 DOI: 10.1097/HCO.0000000000000842] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
133 Sciarrillo CM, Koemel NA, Keirns BH, Banks NF, Rogers EM, Rosenkranz SK, Kurti SP, Jenkins NDM, Emerson SR. Who would benefit most from postprandial lipid screening? Clin Nutr 2021;40:4762-71. [PMID: 34242916 DOI: 10.1016/j.clnu.2021.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Demonty I, Langlois K, Greene-Finestone LS, Zoka R, Nguyen L. Proportions of long-chain ω-3 fatty acids in erythrocyte membranes of Canadian adults: Results from the Canadian Health Measures Survey 2012-2015. Am J Clin Nutr 2021;113:993-1008. [PMID: 33675340 DOI: 10.1093/ajcn/nqaa401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
135 Sarak B, Savu A, Kaul P, McAlister FA, Welsh RC, Yan AT, Goodman SG. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. Circ Cardiovasc Qual Outcomes 2021;14:e006646. [PMID: 33813856 DOI: 10.1161/CIRCOUTCOMES.120.006646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
136 Farukhi Z, Mora S. Assessing the dyslipidemias: to fast or not to fast? Curr Opin Endocrinol Diabetes Obes 2021;28:97-103. [PMID: 33481424 DOI: 10.1097/MED.0000000000000615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Manno M, Cappelletti P, Moretti M, Stenner E, Veneziani F, Burgio MA, Di Pietro M, Morandini M, Marino G, Viola J, Mazzei D, Rubin D, Di Maria D, Cassin M, Gamboni A, Malloggi L, Galli GA, Miconi V, Gruppo di Studio sui Marcatori Miocardici (GdS MM) della Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMeL). Survey on lipid diagnostics in Italy from the Working Group on Myocardial Markers (GdS MM) of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL): results and recommendations for reporting. Riv Ital Med Lab 2021;17. [DOI: 10.23736/s1825-859x.21.00095-5] [Reference Citation Analysis]
138 Furlan L, Azcarate P, Redberg RF. Screening for Lipoprotein(a) Levels in Persons at Low Risk for Cardiovascular Disease: A Teachable Moment. JAMA Intern Med 2021;181:539. [PMID: 33464278 DOI: 10.1001/jamainternmed.2020.8367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
139 Hu X, Li H, Zhao X, Zhou R, Liu H, Sun Y, Fan Y, Shi Y, Qiao S, Liu S, Liu H, Zhang S. Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome. Theranostics 2021;11:5778-93. [PMID: 33897881 DOI: 10.7150/thno.55946] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
140 Wang L, Zhou W, Guo M, Hua Y, Zhou B, Li X, Zhang X, Dong J, Yang X, Wang Y, Wu Y, She J, Mu J. The gut microbiota is associated with clinical response to statin treatment in patients with coronary artery disease. Atherosclerosis 2021;325:16-23. [PMID: 33878520 DOI: 10.1016/j.atherosclerosis.2021.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
141 Higgins V, White-Al Habeeb N, Venner AA, Bailey D, Collier C, Adeli K; Canadian Society of Clinical Chemists Working Group on Reference Interval Harmonisation. A Snapshot of Lipid-Reporting Practices in Canadian Clinical Laboratories: An Urgent Need for Harmonisation. Can J Cardiol 2021;37:933-7. [PMID: 33775880 DOI: 10.1016/j.cjca.2021.03.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
142 Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol 2021;37:1129-50. [PMID: 33781847 DOI: 10.1016/j.cjca.2021.03.016] [Cited by in Crossref: 105] [Cited by in F6Publishing: 119] [Article Influence: 105.0] [Reference Citation Analysis]
143 Swerdlow DI, Rider DA, Yavari A, Lindholm MW, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res 2021:cvab100. [PMID: 33769464 DOI: 10.1093/cvr/cvab100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
144 Al Hamarneh YN, Marra C, Gniadecki R, Keeling S, Morgan A, Tsuyuki R. RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. BMJ Open 2021;11:e043612. [PMID: 33762234 DOI: 10.1136/bmjopen-2020-043612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
145 Glenn AJ, Hernández-Alonso P, Kendall CWC, Martínez-González MÁ, Corella D, Fitó M, Martínez JA, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem JL, Bueno-Cavanillas A, Tur JA, Celada SR, Pintó X, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Mas-Fontao S, Daimiel L, Ros E, Jenkins DJA, Toledo E, Sorlí JV, Castañer O, Abete I, Rodriguez AM, Barceló OF, Oncina-Canovas A, Konieczna J, Garcia-Rios A, Casas R, Gómez-Pérez AM, Santos-Lozano JM, Vazquez-Ruiz Z, Portolés O, Schröder H, Zulet MA, Eguaras S, Lete IS, Zomeño MD, Sievenpiper JL, Salas-Salvadó J. Longitudinal changes in adherence to the portfolio and DASH dietary patterns and cardiometabolic risk factors in the PREDIMED-Plus study. Clin Nutr 2021;40:2825-36. [PMID: 33933749 DOI: 10.1016/j.clnu.2021.03.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
146 Zeng L, Ye Z, Li Y, Zhou Y, Shi Q, Hu T, Fu M, Wu C, Tian H, Li S. Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation. Front Cardiovasc Med 2021;8:638663. [PMID: 33796571 DOI: 10.3389/fcvm.2021.638663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
147 Wilson DP, Koschinsky ML, Moriarty PM. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). Curr Opin Endocrinol Diabetes Obes 2021;28:159-73. [PMID: 33534258 DOI: 10.1097/MED.0000000000000624] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
148 Burén J, Ericsson M, Damasceno NRT, Sjödin A. A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. Nutrients 2021;13:814. [PMID: 33801247 DOI: 10.3390/nu13030814] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
149 Kanagalingam T, Lazarte J, Wong DKH, Hegele RA. Liver Injury Associated With Ezetimibe Monotherapy. CJC Open 2021;3:195-7. [PMID: 33644733 DOI: 10.1016/j.cjco.2020.09.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
150 Krahn T, Martel M, Sapir-Pichhadze R, Kronfli N, Falutz J, Guaraldi G, Lebouche B, Klein MB, Wong P, Deschenes M, Ghali P, Sebastiani G. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. J Infect Dis 2020;222:787-97. [PMID: 32249283 DOI: 10.1093/infdis/jiaa170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
151 Turgeon RD, Sedlak T. Use of Preventive Medications in Patients With Nonobstructive Coronary Artery Disease: Analysis of the PROMISE Trial. CJC Open 2021;3:159-66. [PMID: 33644729 DOI: 10.1016/j.cjco.2020.09.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021;77:1439-50. [PMID: 33736827 DOI: 10.1016/j.jacc.2021.01.027] [Cited by in Crossref: 43] [Cited by in F6Publishing: 53] [Article Influence: 43.0] [Reference Citation Analysis]
153 Jamthikar AD, Puvvula A, Gupta D, Johri AM, Nambi V, Khanna NN, Saba L, Mavrogeni S, Laird JR, Pareek G, Miner M, Sfikakis PP, Protogerou A, Kitas GD, Nicolaides A, Sharma AM, Viswanathan V, Rathore VS, Kolluri R, Bhatt DL, Suri JS. Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. Int Angiol 2021;40. [DOI: 10.23736/s0392-9590.20.04538-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
154 Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, Ginsberg HN, Goldberg IJ, Murad MH, Subramanian S, Tannock LR. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2020;105:dgaa674. [PMID: 32951056 DOI: 10.1210/clinem/dgaa674] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 38.0] [Reference Citation Analysis]
155 Taha HSED, Badran HM, Kandil H, Farag N, Oraby A, El Sharkawy M, Shokry K, Fawzy F, Mahrous H, Bahgat J, Samy M, Shaker MM. Egyptian practical guidance in lipid management 2020. Egypt Heart J 2021;73:17. [PMID: 33620601 DOI: 10.1186/s43044-021-00140-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
156 Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Can J Cardiol 2021;37:733-43. [PMID: 33610690 DOI: 10.1016/j.cjca.2021.02.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
157 Feldman F, Koudoufio M, Desjardins Y, Spahis S, Delvin E, Levy E. Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. Nutrients 2021;13:672. [PMID: 33669729 DOI: 10.3390/nu13020672] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
158 Nishikawa Y. Effects and Issues of Diet Fat on Cardiovascular Metabolism. New Insights Into Metabolic Syndrome 2021. [DOI: 10.5772/intechopen.93261] [Reference Citation Analysis]
159 Ezhov MV, Tmoyan NA, Afanasieva OI, Afanasieva MI, Pokrovsky SN. Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. Biomolecules 2021;11:257. [PMID: 33578899 DOI: 10.3390/biom11020257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
160 Devaraj S, Jialal I. Optimum lipid testing for diabetic patients to enhance clinical care. Diabetes Metab Syndr 2021;15:461-4. [PMID: 33607521 DOI: 10.1016/j.dsx.2021.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Chow ALS, Alhassani SD, Crean AM, Small GR. Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis. J Clin Med 2021;10:625. [PMID: 33562179 DOI: 10.3390/jcm10040625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
162 Sievenpiper JL. Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity. Nutr Rev 2020;78:69-77. [PMID: 32728757 DOI: 10.1093/nutrit/nuz082] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
163 Lust CAC, Bi X, Henry CJ, Ma DWL. Development of Fatty Acid Reference Ranges and Relationship with Lipid Biomarkers in Middle-Aged Healthy Singaporean Men and Women. Nutrients 2021;13:435. [PMID: 33572735 DOI: 10.3390/nu13020435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Tran DT, Palfrey D, Welsh R. The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. Pharmacoecon Open 2021;5:425-35. [PMID: 33484443 DOI: 10.1007/s41669-021-00257-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
165 Medeiros LM, Stahlschmidt R, Ferracini AC, Souza CM, Juliato CRT, Mazzola PG. Switching of Hormone Therapies in Breast Cancer Women. Rev Bras Ginecol Obstet 2021;43:185-9. [PMID: 33465792 DOI: 10.1055/s-0040-1719149] [Reference Citation Analysis]
166 Kaiser SE. Elevated Lipoprotein(A) in Children and Adolescents: Early Identification is Key for Successful Intervention. International Journal of Cardiovascular Sciences 2021;34:19-20. [DOI: 10.36660/ijcs.20200303] [Reference Citation Analysis]
167 Aggarwal P, Sinha SK, Khanra D, Nath RK, Gujral J, Reddy KK, Mukherjee A. Comparison of original and modified Q risk 2 risk score with Framingham risk score - An Indian perspective. Indian Heart J 2021;73:353-8. [PMID: 34154755 DOI: 10.1016/j.ihj.2021.01.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open Heart 2020;7:e001396. [PMID: 33443127 DOI: 10.1136/openhrt-2020-001396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
169 Ko DT, Sivaswamy A, Sud M, Kotrri G, Azizi P, Koh M, Austin PC, Lee DS, Roifman I, Thanassoulis G, Tu K, Udell JA, Wijeysundera HC, Anderson TJ. Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations. CMAJ 2020;192:E442-9. [PMID: 32392491 DOI: 10.1503/cmaj.190848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
170 Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, Bolton T, Burgess S, Dudbridge F, Guo Q, Sofianopoulou E, Stevens D, Thompson JR, Butterworth AS, Wood A, Danesh J, Samani NJ, Inouye M, Di Angelantonio E. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med 2021;18:e1003498. [PMID: 33444330 DOI: 10.1371/journal.pmed.1003498] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 44.0] [Reference Citation Analysis]
171 Ong KL, McClelland RL, Allison MA, Cushman M, Garg PK, Tsai MY, Rye KA, Tabet F. Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism 2021;116:154706. [PMID: 33421505 DOI: 10.1016/j.metabol.2021.154706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
172 Lee CT, Eastman SE, Arcinas LA, Asselin CY, Cheung D, Mayba A, Zhu A, Strzelczyk J, Maycher B, Memauri B, Kirkpatrick IDC, Jassal DS. Prevalence and Functional Implication of Silent Coronary Artery Disease in Marathon Runners Over 40 Years of Age: The MATCH-40 Study. CJC Open 2021;3:595-602. [PMID: 34027364 DOI: 10.1016/j.cjco.2020.12.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Blais N, Adam J, Nguyen J, Grégoire JC. Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib. Current Oncology 2021;28:265-72. [DOI: 10.3390/curroncol28010029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
174 Brown AS, Dababneh EG, Chaus A, Chyzhyk V, Marinescu V, Pyslar N. Genetic Disorders of Lipoprotein Metabolism. Contemporary Cardiology 2021. [DOI: 10.1007/978-3-030-56514-5_3] [Reference Citation Analysis]
175 Chianetta R, Sachinidis A, Nikolic D, Luzzu LM, Stoian AP, Toth PP, Rizzo M. Nutraceuticals and Cardiovascular Disease. Nutraceuticals and Cardiovascular Disease 2021. [DOI: 10.1007/978-3-030-62632-7_5] [Reference Citation Analysis]
176 Nordestgaard BG, Varbo A. Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology 2021. [DOI: 10.1007/978-3-030-56514-5_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Brandt EJ. C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. Contemporary Cardiology 2021. [DOI: 10.1007/978-3-030-56514-5_30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Guo C, Cao H, Shan G, Zhao W, Zhang H, Niu K, Cui Z, Tang N, Liu K, Pan L, Han X, Wang Z, Meng G, Sun J, Shan A, Yan Y, He H, Xu Z, Cao Y, Peng W, Sun Y, Xie Y, Liu X, Li B, Wen F, Zhang L. Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study. Ann Transl Med 2021;9:26. [PMID: 33553319 DOI: 10.21037/atm-20-3899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
179 Touma J, Bosse C, Marzelle J, Desgranges P, Cochennec F. Rottura dell’aneurisma dell’aorta addominale: tecniche specifiche. EMC - Tecniche Chirurgiche Vascolare 2021;26:1-25. [DOI: 10.1016/s1283-0801(20)44532-7] [Reference Citation Analysis]
180 Touma J, Bosse C, Marzelle J, Desgranges P, Cochennec F. Rupturas de aneurisma de la aorta abdominal: técnicas específicas. EMC - Cirugía General 2021;21:1-26. [DOI: 10.1016/s1634-7080(21)45066-4] [Reference Citation Analysis]
181 Langlois M, Nordestgaard B, Langsted A, Chapman M, Aakre K, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps O, Duff C, Eckardstein VA, Hammerer-lercher A, Kamstrup P, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley A, Rifai N, Ros E, Stankovic S, Stavljenic-rukavina A, Sypniewska G, Watts G, Wiklund O, Laitinen P. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Lab sluzh 2021;10:45. [DOI: 10.17116/labs20211001145] [Reference Citation Analysis]
182 Zhao S, Guo D, Zhu Q, Dou W, Guan W. Display of Microbial Glucose Dehydrogenase and Cholesterol Oxidase on the Yeast Cell Surface for the Detection of Blood Biochemical Parameters. Biosensors (Basel) 2020;11:13. [PMID: 33396921 DOI: 10.3390/bios11010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Myette-Côté É, St-Pierre V, Beaulieu S, Castellano CA, Fortier M, Plourde M, Bocti C, Fulop T, Cunnane SC. The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment. Prostaglandins Leukot Essent Fatty Acids 2021;169:102236. [PMID: 33906081 DOI: 10.1016/j.plefa.2020.102236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
184 Cao YX, Zhang HW, Jin JL, Liu HH, Zhang Y, Zhang M, Gao Y, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Wang LF, Gao RL, Li JJ. Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thromb Haemost 2021;121:1161-8. [PMID: 33339063 DOI: 10.1055/a-1340-2109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Bigazzi F, Minichilli F, Sbrana F, Pino BD, Corsini A, Watts GF, Sirtori CR, Ruscica M, Sampietro T. Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158869. [PMID: 33333178 DOI: 10.1016/j.bbalip.2020.158869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
186 Langer A, Tan M, Goodman SG, Grégoire J, Lin PJ, Mancini GBJ, Stone JA, Leiter LA. Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. Int J Clin Pract 2021;75:e13861. [PMID: 33244861 DOI: 10.1111/ijcp.13861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
187 Gouda P, Welsh RC, Padarath M, Grégoire JC, Hegele RA, Gupta M. Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. CJC Open 2020;2:625-31. [PMID: 33305223 DOI: 10.1016/j.cjco.2020.08.009] [Reference Citation Analysis]
188 Castiel J, Chen-Tournoux A, Thanassoulis G, Goldfarb M. A Patient-Led Referral Strategy for Cardiovascular Screening of Family and Household Members at the Time of Cardiac Intensive Care Unit Admission. CJC Open 2020;2:506-13. [PMID: 33305210 DOI: 10.1016/j.cjco.2020.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Lan NSR, Burns K, Bell DA, Watts GF. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Curr Opin Endocrinol Diabetes Obes 2021;28:104-13. [PMID: 33278128 DOI: 10.1097/MED.0000000000000594] [Reference Citation Analysis]
190 Guo Y, Wheldon CW, Shao H, Pepine CJ, Handberg EM, Shenkman EA, Bian J. Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults. J Am Heart Assoc 2020;9:e018233. [PMID: 33317368 DOI: 10.1161/JAHA.120.018233] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
191 Huang Z, Shui X, Ling Y, Zhou L, Shi W, Luo Y, Li S, Zhu J, Yu S, Liu J. Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. Clin Cardiol 2020. [PMID: 33289114 DOI: 10.1002/clc.23520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, Zhao YL, Qian J, Jin YZ, Liu YW, Wang SH, He SH, Yang P, Wu J, Lu F, Hou ZS. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial. Chin Med J (Engl) 2020;134:185-92. [PMID: 33273369 DOI: 10.1097/CM9.0000000000001257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
193 Langslet G, Hovingh GK, Guyton JR, Baccara-Dinet MT, Letierce A, Manvelian G, Farnier M. Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. Cardiovasc Drugs Ther 2020;34:515-23. [PMID: 32363493 DOI: 10.1007/s10557-020-06984-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 2020;6:e12108. [PMID: 33283039 DOI: 10.1002/trc2.12108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
195 Campbell DJT, Lee-Krueger RCW, McBrien K, Anderson T, Quan H, Leung AA, Chen G, Lu M, Naugler C, Butalia S. Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada. BMJ Open 2020;10:e038469. [PMID: 33234627 DOI: 10.1136/bmjopen-2020-038469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 White AMB, Mishcon HR, Redwanski JL, Hills RD. Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers. JCM 2020;9:3748. [DOI: 10.3390/jcm9113748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Lavie G, Hoshen M, Leibowitz M, Benis A, Akriv A, Balicer R, Reges O. Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality. Am J Med 2021;134:643-52. [PMID: 33217370 DOI: 10.1016/j.amjmed.2020.09.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
198 Xu W, Guan H, Gao D, Wang Z, Ba Y, Yang H, Shen W, Lian J, Zhou J. The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels. Diabetes Metab Syndr Obes 2020;13:4297-310. [PMID: 33209043 DOI: 10.2147/DMSO.S279814] [Reference Citation Analysis]
199 Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes 2021;28:181-7. [PMID: 33229929 DOI: 10.1097/MED.0000000000000597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
200 Bailey AL, Campbell CL. The U.S. Department of Veterans Affairs and U.S. Department of Defense Guideline for the Management of Dyslipidemia: Is Moderate Risk Reduction Enough? Ann Intern Med 2020;173:846-847. [DOI: 10.7326/m20-6125] [Reference Citation Analysis]
201 Jamthikar AD, Gupta D, Mantella LE, Saba L, Laird JR, Johri AM, Suri JS. Multiclass machine learning vs. conventional calculators for stroke/CVD risk assessment using carotid plaque predictors with coronary angiography scores as gold standard: a 500 participants study. Int J Cardiovasc Imaging 2021;37:1171-87. [DOI: 10.1007/s10554-020-02099-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
202 Hsu CY, Chen WJ, Chen HM, Tsai HY, Hsiao FY. Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors. J Clin Pharm Ther 2021;46:415-23. [PMID: 33180353 DOI: 10.1111/jcpt.13299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
203 Gupta M. Addressing atherosclerotic cardiovascular disease risk in South Asians: A daunting task ahead. Atherosclerosis 2020;315:76-8. [PMID: 33172687 DOI: 10.1016/j.atherosclerosis.2020.10.892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Gómez-Sánchez M, Gómez-Sánchez L, Patino-Alonso MC, Alonso-Domínguez R, Sánchez-Aguadero N, Recio-Rodríguez JI, González-Sánchez J, García-Ortiz L, Gómez-Marcos MA; EVA group. Relationship of healthy vascular aging with lifestyle and metabolic syndrome in the general Spanish population. The EVA study. Rev Esp Cardiol (Engl Ed) 2021;74:854-61. [PMID: 33132098 DOI: 10.1016/j.rec.2020.06.040] [Reference Citation Analysis]
205 Bavishi A, Lloyd-Jones DM, Ning H, Vu THT, Yancy CW, Shah SJ, Carnethon M, Khan SS. Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. PLoS One 2020;15:e0240567. [PMID: 33141828 DOI: 10.1371/journal.pone.0240567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
206 Nestel PJ, Beilin LJ, Clifton PM, Watts GF, Mori TA. Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. Heart Lung Circ 2021;30:163-79. [PMID: 33158734 DOI: 10.1016/j.hlc.2020.08.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
207 Hussein ME, Hakkola J. Mnemonic to assist in the treatment of NSTE-ACS. Nurse Pract 2020;45:48-55. [PMID: 33093397 DOI: 10.1097/01.NPR.0000718512.98673.72] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Benincasa G, de Candia P, Costa D, Faenza M, Mansueto G, Ambrosio G, Napoli C. Network Medicine Approach in Prevention and Personalized Treatment of Dyslipidemias. Lipids 2021;56:259-68. [PMID: 33118184 DOI: 10.1002/lipd.12290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
209 de Vries TI, Visseren FLJ. Cardiovascular risk prediction tools made relevant for GPs and patients. Heart 2020:heartjnl-2019-316377. [PMID: 33077500 DOI: 10.1136/heartjnl-2019-316377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
210 Simha V. Management of hypertriglyceridemia. BMJ. [DOI: 10.1136/bmj.m3109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
211 Pei L, Xiao H, Lai F, Li Z, Li Z, Yue S, Chen H, Li Y, Cao X. Early postpartum dyslipidemia and its potential predictors during pregnancy in women with a history of gestational diabetes mellitus. Lipids Health Dis 2020;19:220. [PMID: 33036614 DOI: 10.1186/s12944-020-01398-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
212 Nestel PJ, Beilin LJ, Mori TA. Changing dietary approaches to prevent cardiovascular disease. Curr Opin Lipidol 2020;31:313-23. [PMID: 33027224 DOI: 10.1097/MOL.0000000000000709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
213 Jamthikar AD, Gupta D, Saba L, Khanna NN, Viskovic K, Mavrogeni S, Laird JR, Sattar N, Johri AM, Pareek G, Miner M, Sfikakis PP, Protogerou A, Viswanathan V, Sharma A, Kitas GD, Nicolaides A, Kolluri R, Suri JS. Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. Comput Biol Med 2020;126:104043. [PMID: 33065389 DOI: 10.1016/j.compbiomed.2020.104043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
214 Sethwala AM, Goh I, Amerena JV. Combating Inflammation in Cardiovascular Disease. Heart Lung Circ 2021;30:197-206. [PMID: 33039279 DOI: 10.1016/j.hlc.2020.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
215 Welsh P, Welsh C, Celis-Morales CA, Brown R, Ho FK, Ferguson LD, Mark PB, Lewsey J, Gray SR, Lyall DM, Gill JMR, Pell JP, de Lemos JA, Willeit P, Sattar N. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol 2020:zwaa063. [PMID: 33624048 DOI: 10.1093/eurjpc/zwaa063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
216 Fitchett DH, Leiter LA, Lin P, Pickering J, Welsh R, Stone J, Gregoire J, McFarlane P, Langer A, Gupta A, Goodman SG. Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open 2020;2:402-15. [PMID: 32995726 DOI: 10.1016/j.cjco.2020.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Singh G, Hussain Y, Xu Z, Sholle E, Michalak K, Dolan K, Lee BC, van Rosendael AR, Fatima Z, Peña JM, Wilson PWF, Gotto AM Jr, Shaw LJ, Baskaran L, Al'Aref SJ. Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. PLoS One 2020;15:e0239934. [PMID: 32997716 DOI: 10.1371/journal.pone.0239934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
218 Ghazizadeh H, Kathryn Bohn M, Ghaffarian Zirak R, Kamel Khodabandeh A, Zare-Feyzabadi R, Saberi-Karimian M, Timar A, Jaberi N, Mohammadi-Bajgiran M, Sharifan P, Tayefi M, Silakhori S, Emamian M, Oladi MR, Esmaily H, Ferns GA, Adeli K, Ghayour-Mobarhan M. Comprehensive laboratory reference intervals for routine biochemical markers and pro-oxidant-antioxidant balance (PAB) in male adults. J Clin Lab Anal 2020;34:e23470. [PMID: 32986247 DOI: 10.1002/jcla.23470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
219 Panagiotopoulou O, Chiesa ST, Tousoulis D, Charakida M. Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. Curr Med Chem 2020;27:4494-521. [PMID: 31453780 DOI: 10.2174/0929867326666190827151012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Wang R, Kapoor A, Lindsay P, Goia C, Yu AYX, Gladstone DJ, Swartz RH. Reduction in Stroke After Transient Ischemic Attack in a Province-Wide Cohort Between 2003 and 2015. Can J Neurol Sci 2021;48:335-43. [PMID: 32959741 DOI: 10.1017/cjn.2020.205] [Reference Citation Analysis]
221 Sun CJ, Brisson D, Gaudet D, Ooi TC. Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers. J Clin Lipidol 2020;14:825-36. [PMID: 33032940 DOI: 10.1016/j.jacl.2020.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
222 Rosenson RS, Colantonio LD, Goonewardena SN. Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention. J Am Coll Cardiol 2020;76:1451-4. [PMID: 32943163 DOI: 10.1016/j.jacc.2020.07.050] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Quan S, Chen G, Padwal RS, McAlister FA, Tran KC, Campbell NRC, Liang Z, Feng Y, Rabi DM, Leung AA; for Hypertension Canada’s Research, Evaluation Committee. Frequency of laboratory testing and associated abnormalities in patients with hypertension. J Clin Hypertens (Greenwich) 2020;22:2077-83. [PMID: 32951340 DOI: 10.1111/jch.14040] [Reference Citation Analysis]
224 Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. BMC Cardiovasc Disord 2020;20:418. [PMID: 32942999 DOI: 10.1186/s12872-020-01697-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, Burgess S, Willeit P, Bolton T, Moons KGM, van der Schouw YT, Selmer R, Khaw KT, Gudnason V, Assmann G, Amouyel P, Salomaa V, Kivimaki M, Nordestgaard BG, Blaha MJ, Kuller LH, Brenner H, Gillum RF, Meisinger C, Ford I, Knuiman MW, Rosengren A, Lawlor DA, Völzke H, Cooper C, Marín Ibañez A, Casiglia E, Kauhanen J, Cooper JA, Rodriguez B, Sundström J, Barrett-Connor E, Dankner R, Nietert PJ, Davidson KW, Wallace RB, Blazer DG, Björkelund C, Donfrancesco C, Krumholz HM, Nissinen A, Davis BR, Coady S, Whincup PH, Jørgensen T, Ducimetiere P, Trevisan M, Engström G, Crespo CJ, Meade TW, Visser M, Kromhout D, Kiechl S, Daimon M, Price JF, Gómez de la Cámara A, Wouter Jukema J, Lamarche B, Onat A, Simons LA, Kavousi M, Ben-Shlomo Y, Gallacher J, Dekker JM, Arima H, Shara N, Tipping RW, Roussel R, Brunner EJ, Koenig W, Sakurai M, Pavlovic J, Gansevoort RT, Nagel D, Goldbourt U, Barr ELM, Palmieri L, Njølstad I, Sato S, Monique Verschuren WM, Varghese CV, Graham I, Onuma O, Greenland P, Woodward M, Ezzati M, Psaty BM, Sattar N, Jackson R, Ridker PM, Cook NR, D'Agostino RB, Thompson SG, Danesh J, Di Angelantonio E; Emerging Risk Factors Collaboration. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. Eur Heart J 2019;40:621-31. [PMID: 30476079 DOI: 10.1093/eurheartj/ehy653] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 31.0] [Reference Citation Analysis]
226 Dong I, Klodas E. Healthcare Cost Implications of Utilizing a Dietary Intervention to Lower LDL Cholesterol: Proof of Concept Actuarial Analysis and Recommendations. Curr Cardiol Rep 2020;22:138. [PMID: 32910320 DOI: 10.1007/s11886-020-01397-9] [Reference Citation Analysis]
227 Goldenberg R, Bell A, Cheng W, Fils-Aimé N, Burrows M, Blavignac J, Parron E, Barakat M. Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. Diabetes Res Clin Pract 2020;170:108416. [PMID: 32891688 DOI: 10.1016/j.diabres.2020.108416] [Reference Citation Analysis]
228 Afshar M, Rong J, Zhan Y, Chen HY, Engert JC, Sniderman AD, Larson MG, Vasan RS, Thanassoulis G. Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study. J Am Heart Assoc 2020;9:e014711. [PMID: 32892691 DOI: 10.1161/JAHA.119.014711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
229 Khoury M, McCrindle BW. The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population. Can J Cardiol 2020;36:1372-83. [PMID: 32735868 DOI: 10.1016/j.cjca.2020.03.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Pintó X, Masana L, Civeira F, Real J, Ibarretxe D, Candas B, Puzo J, Luis Díaz J, Amigó N, Esteban M, Valdivielso P. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). Clínica e Investigación en Arteriosclerosis (English Edition) 2020;32:219-229. [DOI: 10.1016/j.artere.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Trautwein EA, McKay S. The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. Nutrients 2020;12:E2671. [PMID: 32883047 DOI: 10.3390/nu12092671] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 22.0] [Reference Citation Analysis]
232 Harris KC, Mccrindle BW. “The Child Is the Father of the Man”—Pediatric Preventive Cardiology. Canadian Journal of Cardiology 2020;36:1329-1332. [DOI: 10.1016/j.cjca.2020.07.007] [Reference Citation Analysis]
233 Lazarte J, Berberich AJ, Wang J, Hegele RA. A cautionary tale: Is this APOB whole-gene duplication actually pathogenic? Journal of Clinical Lipidology 2020;14:631-5. [DOI: 10.1016/j.jacl.2020.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Jamthikar AD, Gupta D, Puvvula A, Johri AM, Khanna NN, Saba L, Mavrogeni S, Laird JR, Pareek G, Miner M, Sfikakis PP, Protogerou A, Kitas GD, Kolluri R, Sharma AM, Viswanathan V, Rathore VS, Suri JS. Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging. Rheumatol Int 2020;40:1921-39. [PMID: 32857281 DOI: 10.1007/s00296-020-04691-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
235 Engeda JC, Lhachimi SK, Rosamond WD, Lund JL, Keyserling TC, Safford MM, Colantonio LD, Muntner P, Avery CL, Aminde L. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study. PLoS Med 2020;17:e1003280. [DOI: 10.1371/journal.pmed.1003280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med 2020;287:2-18. [PMID: 31858669 DOI: 10.1111/joim.12981] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 25.0] [Reference Citation Analysis]
237 M Grant S, J Glenn A, M S Wolever T, G Josse R, L O'Connor D, Thompson A, D Noseworthy R, Seider M, Sobie M, Bhatti G, Cavanagh J, Jones E, B Darling P. Evaluation of Glycemic Index Education in People Living with Type 2 Diabetes: Participant Satisfaction, Knowledge Uptake, and Application. Nutrients 2020;12:E2416. [PMID: 32806563 DOI: 10.3390/nu12082416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Pintó X, Masana L, Civeira F, Real J, Ibarretxe D, Candas B, Puzo J, Díaz JL, Amigó N, Esteban M, Valdivielso P. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). Clin Investig Arterioscler 2020;32:219-29. [PMID: 32798078 DOI: 10.1016/j.arteri.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
239 Grubic N, Colledanchise KN, Liblik K, Johri AM. The Role of Carotid and Femoral Plaque Burden in the Diagnosis of Coronary Artery Disease. Curr Cardiol Rep 2020;22:121. [PMID: 32778953 DOI: 10.1007/s11886-020-01375-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
240 Rached F, Santos RD. The Role of Statins in Current Guidelines. Curr Atheroscler Rep 2020;22. [DOI: 10.1007/s11883-020-00861-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
241 Aljenedil S, Alothman L, Bélanger AM, Brown L, Lahijanian Z, Bergeron J, Couture P, Baass A, Ruel I, Brisson D, Khoury E, Gaudet D, Genest J. Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. Atherosclerosis 2020;310:54-63. [PMID: 32906018 DOI: 10.1016/j.atherosclerosis.2020.07.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
242 Tran DT, Palfrey D, Lo TKT, Welsh R. Outcome and Cost of Optimal Control of Dyslipidemia in Adults With High Risk for Cardiovascular Disease. Can J Cardiol 2021;37:66-76. [PMID: 32738207 DOI: 10.1016/j.cjca.2020.03.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ES, Park MM, Becher H, Sillesen H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. Journal of the American Society of Echocardiography 2020;33:917-33. [DOI: 10.1016/j.echo.2020.04.021] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 33.0] [Reference Citation Analysis]
244 Jamthikar A, Gupta D, Saba L, Khanna NN, Araki T, Viskovic K, Mavrogeni S, Laird JR, Pareek G, Miner M, Sfikakis PP, Protogerou A, Viswanathan V, Sharma A, Nicolaides A, Kitas GD, Suri JS. Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models. Cardiovasc Diagn Ther. 2020;10:919-938. [PMID: 32968651 DOI: 10.21037/cdt.2020.01.07] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
245 Jamthikar A, Gupta D, Cuadrado-Godia E, Puvvula A, Khanna NN, Saba L, Viskovic K, Mavrogeni S, Turk M, Laird JR, Pareek G, Miner M, Sfikakis PP, Protogerou A, Kitas GD, Shankar C, Nicolaides A, Viswanathan V, Sharma A, Suri JS. Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on "Integrated Vascular Age" instead of "Chronological Age": a multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. Cardiovasc Diagn Ther. 2020;10:939-954. [PMID: 32968652 DOI: 10.21037/cdt.2020.01.16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
246 Kampar P. The Correlation Between Lipid Profile and Xanthelasma. BIKK 2020;32:119. [DOI: 10.20473/bikk.v32.2.2020.119-125] [Reference Citation Analysis]
247 Migliaccio S, Brasacchio C, Pivari F, Salzano C, Barrea L, Muscogiuri G, Savastano S, Colao A; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group. What is the best diet for cardiovascular wellness? A comparison of different nutritional models. Int J Obes Suppl 2020;10:50-61. [PMID: 32714512 DOI: 10.1038/s41367-020-0018-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
248 Nikhanj A, Nichols BM, Wang K, Siddiqi ZA, Oudit GY. Evaluating the Diagnostic and Prognostic Value of Biomarkers for Heart Disease and Major Adverse Cardiac Events in Patients With Muscular Dystrophy. Eur Heart J Qual Care Clin Outcomes 2020:qcaa059. [PMID: 32687175 DOI: 10.1093/ehjqcco/qcaa059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
249 Vikulova DN, Skorniakov IS, Bitoiu B, Brown C, Theberge E, Fordyce CB, Francis GA, Humphries KH, Mancini GBJ, Pimstone SN, Brunham LR. Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. Am J Prev Cardiol 2020;2:100036. [PMID: 34327459 DOI: 10.1016/j.ajpc.2020.100036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Mortensen MB, Nordestgaard BG. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol 2019;4:1131-8. [PMID: 31577339 DOI: 10.1001/jamacardio.2019.3665] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
251 Sparrow RT, Khan AM, Ferreira-Legere LE, Ko DT, Jackevicius CA, Goodman SG, Anderson TJ, Stacey D, Tiszovszky I, Farkouh ME, Tu JV, Udell JA. Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials. JAMA Cardiol 2019;4:1160-9. [PMID: 31461127 DOI: 10.1001/jamacardio.2019.3066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
252 Chen H, Chen Y, Wu W, Chen Z, Cai Z, Chen Z, Yan X, Wu S. Prolonged hyperlipidemia exposure increases the risk of arterial stiffness in young adults: a cross-sectional study in a cohort of Chinese. BMC Public Health 2020;20:1091. [PMID: 32652962 DOI: 10.1186/s12889-020-09211-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
253 Lazarte J, Hegele RA. Pediatric Dyslipidemia-Beyond Familial Hypercholesterolemia. Can J Cardiol 2020;36:1362-71. [PMID: 32640212 DOI: 10.1016/j.cjca.2020.03.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
254 Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Pletcher MJ, Vittinghoff E, Pencina MJ, Kazi D, Sniderman AD, Moran AE. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiol 2019;4:969-77. [PMID: 31461121 DOI: 10.1001/jamacardio.2019.2851] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
255 Gonen A, Yang X, Yeang C, Alekseeva E, Koschinsky M, Witztum JL, Boffa M, Tsimikas S. Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). J Lipid Res 2020;61:1263-70. [PMID: 32641432 DOI: 10.1194/jlr.RA120000830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
256 Enkhmaa B, Petersen KS, Kris-Etherton PM, Berglund L. Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? Nutrients 2020;12:E2024. [PMID: 32646066 DOI: 10.3390/nu12072024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
257 Park J, Lee JH, Kim KA, Lee SH, Lee YT, Kim WS, Min JJ. Effects of Preoperative Statin on Acute Kidney Injury After Off-Pump Coronary Artery Bypass Grafting. J Am Heart Assoc 2019;8:e010892. [PMID: 30905260 DOI: 10.1161/JAHA.118.010892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
258 Butalia S, Lee-Krueger RCW, McBrien KA, Leung AAC, Anderson TJ, Quan H, Naugler C, Chen G, Campbell DJT. Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. CJC Open 2020;2:530-8. [PMID: 33305213 DOI: 10.1016/j.cjco.2020.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
259 Brownstein AJ, Martin SS. More accurate LDL-C calculation: Externally validated, guideline endorsed. Clinica Chimica Acta 2020;506:149-53. [DOI: 10.1016/j.cca.2020.03.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
260 Mujamammi AH, Alluhaymid YM, Alshibani MG, Alotaibi FY, Alzahrani KM, Alotaibi AB, Almasabi AA, Sabi EM. Awareness of cardiovascular disease associated risk factors among Saudis in Riyadh City. J Family Med Prim Care 2020;9:3100-5. [PMID: 32984180 DOI: 10.4103/jfmpc.jfmpc_458_20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
261 Kim S, Choi H, Won CW. Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). Ann Geriatr Med Res 2020;24:91-8. [PMID: 32743329 DOI: 10.4235/agmr.20.0028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
262 Hyun MH, Jang JW, Lee E, An H, Seog Seo H. Baseline, delta, and achieved low-density lipoprotein cholesterol levels and cardiovascular risk in patients on statin therapy: A post-hoc resampling mediation analysis of treating new targets [TNT] trial. Clin Exp Pharmacol Physiol 2020;47:1649-58. [PMID: 32583886 DOI: 10.1111/1440-1681.13367] [Reference Citation Analysis]
263 Kenk M, Grégoire JC, Coté MA, Connelly KA, Davis MK, Dresser G, Ghosh N, Goodman S, Johnson C, Fleshner N. Optimizing screening and management of cardiovascular health in prostate cancer: A review. Can Urol Assoc J 2020;14:E458-64. [PMID: 32569573 DOI: 10.5489/cuaj.6685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
264 Zolezzi M, Abdallah O, Sankaralingam S. Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment. Risk Manag Healthc Policy 2020;13:623-32. [PMID: 32607030 DOI: 10.2147/RMHP.S231075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
265 Chan J, Rajalingam T, Fossella J, Zhou H, Eisenberg N, Roche-Nagle G. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Ann Vasc Surg 2020;69:197-205. [PMID: 32554202 DOI: 10.1016/j.avsg.2020.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
266 Kaur R, Myrie SB. Association of Dietary Phytosterols with Cardiovascular Disease Biomarkers in Humans. Lipids 2020;55:569-84. [PMID: 32557606 DOI: 10.1002/lipd.12262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
267 Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Curr Cardiol Rep 2020;22:67. [PMID: 32562186 DOI: 10.1007/s11886-020-01323-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
268 Bajaj HS, Brown RE, Jiandani D, Venn K, Al-Asaad H, Khandwala H, Steen O, Abdel-Salam S, Aronson R. Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. Diabetes Obes Metab 2020;22:1722-8. [PMID: 32406601 DOI: 10.1111/dom.14084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
269 Chu A, Han L, Roifman I, Lee DS, Green ME, Jacklin K, Walker J, Sutherland R, Khan S, Frymire E, Tu JV, Shah BR. Trends in cardiovascular care and event rates among First Nations and other people with diabetes in Ontario, Canada, 1996-2015. CMAJ 2019;191:E1291-8. [PMID: 31767704 DOI: 10.1503/cmaj.190899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
270 Mora S, Chang CL, Moorthy MV, Sever PS. Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. JAMA Intern Med 2019;179:898-905. [PMID: 31135812 DOI: 10.1001/jamainternmed.2019.0392] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
271 Gomez-Delgado F, Katsiki N, Lopez-Miranda J, Perez-Martinez P. Dietary habits, lipoprotein metabolism and cardiovascular disease: From individual foods to dietary patterns. Crit Rev Food Sci Nutr 2021;61:1651-69. [PMID: 32515660 DOI: 10.1080/10408398.2020.1764487] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
272 Rehberger Likozar A, Zavrtanik M, Šebeštjen M. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Ann Med 2020;52:162-77. [PMID: 32453609 DOI: 10.1080/07853890.2020.1775287] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
273 Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Cardiovasc Drugs Ther 2019;33:739-48. [PMID: 31655942 DOI: 10.1007/s10557-019-06906-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
274 Goldenberg R, Bell A, Cheng W, Paron E, Fils-Aimé N, Burrows M, Blavignac J, Barakat M. Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry. J Cardiol 2020;76:385-94. [PMID: 32473770 DOI: 10.1016/j.jjcc.2020.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Toth PP. Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. American Journal of Preventive Cardiology 2020;2:100040. [DOI: 10.1016/j.ajpc.2020.100040] [Reference Citation Analysis]
276 Naheeda P, Sharifullah K, Ullah SS, Azeem AM, Shahzad Y, Kinza W. Development of a cost-effective CVD prediction model using lifestyle factors. A cohort study in Pakistan. Afr Health Sci 2020;20:849-59. [PMID: 33163052 DOI: 10.4314/ahs.v20i2.39] [Reference Citation Analysis]
277 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Curr Vasc Pharmacol 2019;17:498-514. [PMID: 31060488 DOI: 10.2174/1570161117666190507110519] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
278 Horne J, Gilliland J, O'Connor C, Seabrook J, Madill J. Enhanced long-term dietary change and adherence in a nutrigenomics-guided lifestyle intervention compared to a population-based (GLB/DPP) lifestyle intervention for weight management: results from the NOW randomised controlled trial. BMJ Nutr Prev Health 2020;3:49-59. [PMID: 33235971 DOI: 10.1136/bmjnph-2020-000073] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
279 Roy N, Gaudet D, Tremblay G, Brisson D. Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. Lipids Health Dis 2020;19:98. [PMID: 32430061 DOI: 10.1186/s12944-020-01287-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
280 Guo Y, Huo J, Wu D, Hao H, Ji X, Zhao E, Nie B, Liu Q. Simvastatin inhibits the adipogenesis of bone marrow‑derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling. Int J Mol Med 2020;46:751-61. [PMID: 32468037 DOI: 10.3892/ijmm.2020.4606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
281 Casey DE Jr, Thomas RJ, Bhalla V, Commodore-Mensah Y, Heidenreich PA, Kolte D, Muntner P, Smith SC Jr, Spertus JA, Windle JR, Wozniak GD, Ziaeian B. 2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2019;74:2661-706. [PMID: 31732293 DOI: 10.1016/j.jacc.2019.10.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
282 Tsimikas S, Stroes ES. The dedicated “Lp(a) clinic”: A concept whose time has arrived? Atherosclerosis 2020;300:1-9. [DOI: 10.1016/j.atherosclerosis.2020.03.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]
283 Eltonsy S, Doiron MD, Simard P, Jose C, Sénéchal M, Bouchard DR, LeBlanc R, Bélanger M. Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study. Biomed Res Int 2020;2020:7026530. [PMID: 32420363 DOI: 10.1155/2020/7026530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
284 Biondi RB, Salmazo PS, Bazan SGZ, Hueb JC, de Paiva SAR, Sassaki LY. Cardiovascular Risk in Individuals with Inflammatory Bowel Disease. Clin Exp Gastroenterol 2020;13:107-13. [PMID: 32425576 DOI: 10.2147/CEG.S243478] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
285 Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, Kosiborod M, Leiter LA, Lipska KJ, Newman JD, Welty FK; American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation 2020;141:e779-806. [PMID: 32279539 DOI: 10.1161/CIR.0000000000000766] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 38.0] [Reference Citation Analysis]
286 Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. European Heart Journal 2020;41:2288-99. [DOI: 10.1093/eurheartj/ehaa172] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
287 Blanco Mejia S, Messina M, Li SS, Viguiliouk E, Chiavaroli L, Khan TA, Srichaikul K, Mirrahimi A, Sievenpiper JL, Kris-Etherton P, Jenkins DJA. A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. J Nutr 2019;149:968-81. [PMID: 31006811 DOI: 10.1093/jn/nxz020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 25.5] [Reference Citation Analysis]
288 Yao Y, Pek SX, Toh DWK, Xia X, Kim JE. Effects of fatty acids composition in a breakfast meal on the postprandial lipid responses: a systematic review and meta-analysis of randomised controlled trials. Int J Food Sci Nutr 2020;71:793-803. [PMID: 32223451 DOI: 10.1080/09637486.2020.1744534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
289 Welsh P, Welsh C, Celis-morales CA, Brown R, Ferguson LD, Mark PB, Lewsey J, Gray SR, Lyall DM, Gill JM, Pell JP, de Lemos JA, Willeit P, Sattar N. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions.. [DOI: 10.1101/2020.03.30.20043554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
290 Vuksan V, Sievenpiper JL, Jovanovski E, Jenkins AL, Komishon A, Au-Yeung F, Zurbau A, Ho HVT, Li D, Smircic-Duvnjak L. Effect of soluble-viscous dietary fibre on coronary heart disease risk score across 3 population health categories: data from randomized, double-blind, placebo-controlled trials. Appl Physiol Nutr Metab 2020;45:801-4. [PMID: 32213141 DOI: 10.1139/apnm-2019-0728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
291 Smith GN, Louis JM, Saade GR. Pregnancy and the Postpartum Period as an Opportunity for Cardiovascular Risk Identification and Management. Obstet Gynecol 2019;134:851-62. [PMID: 31503139 DOI: 10.1097/AOG.0000000000003363] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
292 Viswanathan V, Jamthikar AD, Gupta D, Puvvula A, Khanna NN, Saba L, Viskovic K, Mavrogeni S, Turk M, Laird JR, Pareek G, Miner M, Ajuluchukwu J, Sfikakis PP, Protogerou A, Kitas GD, Nicolaides A, Sharma A, Suri JS. Integration of estimated glomerular filtration rate biomarker in image-based cardiovascular disease/stroke risk calculator: a south Asian-Indian diabetes cohort with moderate chronic kidney disease. Int Angiol. 2020;39:290-306. [PMID: 32214072 DOI: 10.23736/s0392-9590.20.04338-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
293 Barry AR, Semchuk WM, Thompson A, LeBras MH, Koshman SL. Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. Can Pharm J (Ott) 2020;153:153-60. [PMID: 32528599 DOI: 10.1177/1715163520909137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Zaric B, Obradovic M, Trpkovic A, Banach M, Mikhailidis DP, Isenovic ER. Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. CMC 2020;27:1021-40. [DOI: 10.2174/0929867326666190903112146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
295 Russell E, Albert A, Côté H, Hsieh A, Nesbitt A, Campbell AR, Maan EJ, Brophy J, Pick N, Murray M. Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. HIV Med 2020;21:418-28. [PMID: 32168418 DOI: 10.1111/hiv.12843] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
296 Shuster S, Awad S. A Rare Case of Statin-Induced Necrotizing Autoimmune Myopathy. AACE Clinical Case Reports 2020;6:e86-e89. [DOI: 10.4158/accr-2019-0547] [Reference Citation Analysis]
297 António M, Ferreira R, Vitorino R, Daniel-da-Silva AL. A simple aptamer-based colorimetric assay for rapid detection of C-reactive protein using gold nanoparticles. Talanta 2020;214:120868. [PMID: 32278414 DOI: 10.1016/j.talanta.2020.120868] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
298 Shin S, Wook Shin D, Young Cho I, Jeong SM, Jung H. Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. Eur J Prev Cardiol 2021;28:864-72. [PMID: 34298552 DOI: 10.1177/2047487320905722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
299 Vallejo-Vaz AJ, Leiter LA, Del Prato S, Taskinen MR, Müller-Wieland D, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Ray KK. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. Eur J Prev Cardiol 2020;27:1663-74. [PMID: 32089006 DOI: 10.1177/2047487320905185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
300 Blaha V, Víšek J, Lášticová M. Atherogenic dyslipidemia typical for metabolic syndrome. Vnitr Lek 2020;66:15-20. [DOI: 10.36290/vnl.2020.003] [Reference Citation Analysis]
301 Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AFG, Bruckert E, Serban MC, Mirrakhimov E, Alnouri F, Reiner Ž, Paragh G, Sahebkar A, Banach M; International Lipid Expert Panel (ILEP). Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res 2020;155:104719. [PMID: 32087236 DOI: 10.1016/j.phrs.2020.104719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
302 Pontremoli R, Bellizzi V, Bianchi S, Bigazzi R, Cernaro V, Del Vecchio L, De Nicola L, Leoncini G, Mallamaci F, Zoccali C, Buemi M. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 2020;33:417-30. [PMID: 32065354 DOI: 10.1007/s40620-020-00707-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
303 Gangadaran S, Bonomini F, Favero G, Rezzani R, Moghadasian MH. Lipids and Diabetes. Bailey's Industrial Oil and Fat Products 2020. [DOI: 10.1002/047167849x.bio119] [Reference Citation Analysis]
304 Cartier L, St-coeur S, Robin A, Lagace M, Douville P. Impact of the Martin/Hopkins modified equation for estimating LDL-C on lipid target attainment in a high risk patient population. Clinical Biochemistry 2020;76:35-7. [DOI: 10.1016/j.clinbiochem.2019.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
305 Lazarte J, Hegele RA. Dyslipidemia Management in Adults With Diabetes. Canadian Journal of Diabetes 2020;44:53-60. [DOI: 10.1016/j.jcjd.2019.07.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
306 Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis 2020;294:46-61. [DOI: 10.1016/j.atherosclerosis.2019.12.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 30.0] [Reference Citation Analysis]
307 Liu HH, Cao YX, Jin JL, Zhang HW, Hua Q, Li YF, Guo YL, Zhu CG, Wu NQ, Xu RX, Chen XH, Li JJ. Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. J Am Heart Assoc 2020;9:e014581. [PMID: 32013705 DOI: 10.1161/JAHA.119.014581] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
308 Higgins V, Adeli K. Postprandial dyslipidemia in insulin resistant states in adolescent populations. J Biomed Res 2020;34:328-42. [PMID: 32934193 DOI: 10.7555/JBR.34.20190094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
309 Toth PP. Statin-Associated Muscle Symptoms Are Real. In: Thompson PD, Taylor BA, editors. Statin-Associated Muscle Symptoms. Cham: Springer International Publishing; 2020. pp. 5-19. [DOI: 10.1007/978-3-030-33304-1_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, Raal FJ, Santos RD, Ray KK. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020;17:360-77. [DOI: 10.1038/s41569-019-0325-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
311 Siedler M, Murad MH, Falck-Ytter Y, Dahm P, Mustafa RA, Sultan S, Morgan RL. Guidelines about physical activity and exercise to reduce cardiometabolic risk factors: protocol for a systematic review and critical appraisal. BMJ Open 2020;10:e032656. [PMID: 31980508 DOI: 10.1136/bmjopen-2019-032656] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
312 Blaha MJ, Whelton SP, Al Rifai M, Dardari Z, Shaw LJ, Al-Mallah MH, Matsushita K, Rozanski A, Rumberger JA, Berman DS, Budoff MJ, Miedema MD, Nasir K, Cainzos-Achirica M. Comparing Risk Scores in the Prediction of Coronary and Cardiovascular Deaths: Coronary Artery Calcium Consortium. JACC Cardiovasc Imaging 2021;14:411-21. [PMID: 31954640 DOI: 10.1016/j.jcmg.2019.12.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
313 Nikhanj A, Yogasundaram H, Miskew Nichols B, Richman-Eisenstat J, Phan C, Bakal JA, Siddiqi ZA, Oudit GY. Cardiac Intervention Improves Heart Disease and Clinical Outcomes in Patients With Muscular Dystrophy in a Multidisciplinary Care Setting. J Am Heart Assoc 2020;9:e014004. [PMID: 31931688 DOI: 10.1161/JAHA.119.014004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
314 Tsimikas S. In Search of Patients With Elevated Lp(a): Seek and Ye Shall Find. J Am Coll Cardiol 2019;73:1040-2. [PMID: 30846098 DOI: 10.1016/j.jacc.2018.12.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
315 Yang YS, Yang BR, Kim MS, Hwang Y, Choi SH. Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. Lipids Health Dis 2020;19:5. [PMID: 31926562 DOI: 10.1186/s12944-019-1158-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
316 Abdelfattah OM, Hassanein M, Saad AM, Abela G, Aldasouqi S. Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. Curr Diabetes Rev 2020;16:949-56. [PMID: 31914915 DOI: 10.2174/1573399816666200107103829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Carrillo-Larco RM, Altez-Fernandez C, Pacheco-Barrios N, Bambs C, Irazola V, Miranda JJ, Danaei G, Perel P. Cardiovascular Disease Prognostic Models in Latin America and the Caribbean: A Systematic Review. Glob Heart 2019;14:81-93. [PMID: 31036306 DOI: 10.1016/j.gheart.2019.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
318 Donato LJ, Meeusen JW. Lipids and lipoproteins. Contemporary Practice in Clinical Chemistry 2020. [DOI: 10.1016/b978-0-12-815499-1.00028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
319 Jenkins WM, Jenkins AE, Jenkins AL, Brydson C. Introduction. The Portfolio Diet for Cardiovascular Disease Risk Reduction 2020. [DOI: 10.1016/b978-0-12-810510-8.09992-1] [Reference Citation Analysis]
320 V H, K A. Cholesterol Absorption. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65897-x] [Reference Citation Analysis]
321 Liu J, Son S, Giancaterino M, Verschoor CP, Narushima M, Moher D. Non-HDL cholesterol level and depression among Canadian elderly—a cross-sectional analysis of the baseline data from the CLSA. FACETS 2020;5:1006-18. [DOI: 10.1139/facets-2020-0039] [Reference Citation Analysis]
322 Mancini GBJ, Bergeron J, Fitchett D, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J. The Canadian Consensus Working Group’s Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. Contemporary Cardiology 2020. [DOI: 10.1007/978-3-030-33304-1_16] [Reference Citation Analysis]
323 Jenkins WM, Jenkins AE, Jenkins AL, Brydson C. The Power of Diet in CVD Risk Factor Reduction. The Portfolio Diet for Cardiovascular Disease Risk Reduction 2020. [DOI: 10.1016/b978-0-12-810510-8.00001-7] [Reference Citation Analysis]
324 Jenkins WM, Jenkins AE, Jenkins AL, Brydson C. Development and Evidence Base. The Portfolio Diet for Cardiovascular Disease Risk Reduction 2020. [DOI: 10.1016/b978-0-12-810510-8.00002-9] [Reference Citation Analysis]
325 Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. The Lancet Diabetes & Endocrinology 2020;8:36-49. [DOI: 10.1016/s2213-8587(19)30388-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 35.5] [Reference Citation Analysis]
326 Martinusen D, Marin JG, Cheng E, Lau W. Chronic Kidney Disease and End Stage Renal Disease. Renal Medicine and Clinical Pharmacy 2020. [DOI: 10.1007/978-3-030-37655-0_4] [Reference Citation Analysis]
327 Langer A, Tan M, Goodman SG, Grégoire J, Lin PJ, Mancini GBJ, Stone JA, Wills C, Spindler C, Leiter LA. GOAL Canada: Physician Education and Support Can Improve Patient Management. CJC Open 2020;2:49-54. [PMID: 32190825 DOI: 10.1016/j.cjco.2019.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
328 Wengrofsky P, Lee J, N. Makaryus A. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. Dyslipidemia 2019. [DOI: 10.5772/intechopen.85772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
329 Cegla J, Neely RG, France M, Ferns G, Byrne CD, Halcox J, Datta D, Capps N, Shoulders C, Qureshi N, Rees A, Main L, Cramb R, Viljoen A, Payne J, Soran H. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019;291:62-70. [DOI: 10.1016/j.atherosclerosis.2019.10.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 22.3] [Reference Citation Analysis]
330 Khan TA, Tayyiba M, Agarwal A, Mejia SB, de Souza RJ, Wolever TM, Leiter LA, Kendall CW, Jenkins DJ, Sievenpiper JL. Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease. Mayo Clinic Proceedings 2019;94:2399-414. [DOI: 10.1016/j.mayocp.2019.05.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
331 Du Z, Yang Y, Zheng J, Li Q, Lin D, Li Y, Fan J, Cheng W, Chen X, Cai Y. Accurate Prediction of Coronary Heart Disease for Patients With Hypertension From Electronic Health Records With Big Data and Machine-Learning Methods: Model Development and Performance Evaluation (Preprint).. [DOI: 10.2196/preprints.17257] [Reference Citation Analysis]
332 Ward NC, Kostner KM, Sullivan DR, Nestel P, Watts GF. Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far? J Clin Med 2019;8:E2073. [PMID: 31783529 DOI: 10.3390/jcm8122073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
333 Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J 2018;39:2589-96. [PMID: 29931232 DOI: 10.1093/eurheartj/ehy334] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 22.7] [Reference Citation Analysis]
334 Le Roy T, Lécuyer E, Chassaing B, Rhimi M, Lhomme M, Boudebbouze S, Ichou F, Haro Barceló J, Huby T, Guerin M, Giral P, Maguin E, Kapel N, Gérard P, Clément K, Lesnik P. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biol 2019;17:94. [PMID: 31775890 DOI: 10.1186/s12915-019-0715-8] [Cited by in Crossref: 79] [Cited by in F6Publishing: 86] [Article Influence: 26.3] [Reference Citation Analysis]
335 Laddu DR, Ozemek C, Hauer TL, Rouleau CR, Campbell TS, Wilton SB, Aggarwal S, Austford L, Arena R. Cardiometabolic responses to cardiac rehabilitation in people with and without diabetes. Int J Cardiol 2020;301:156-62. [PMID: 31806276 DOI: 10.1016/j.ijcard.2019.11.134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
336 Hawley CE, Roefaro J, Forman DE, Orkaby AR. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. Drugs Aging 2019;36:687-99. [PMID: 31049807 DOI: 10.1007/s40266-019-00673-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
337 Hussain MA, Saposnik G, Raju S, Salata K, Mamdani M, Tu JV, Bhatt DL, Verma S, Al-Omran M. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc 2018;7:e009745. [PMID: 30369318 DOI: 10.1161/JAHA.118.009745] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
338 Srivaratharajah K, Abramson BL. Identifying and managing younger women at high risk of cardiovascular disease. CMAJ 2019;191:E159-63. [PMID: 30745400 DOI: 10.1503/cmaj.180053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
339 Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, Tu JV, Forbes TL, Bhatt DL, Verma S, Al-Omran M. Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2018;7:e008657. [PMID: 30371297 DOI: 10.1161/JAHA.118.008657] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 18.0] [Reference Citation Analysis]
340 Dyrbuś K, Gąsior M, Penson P, Ray KK, Banach M. Inclisiran-New hope in the management of lipid disorders? J Clin Lipidol 2020;14:16-27. [PMID: 31879073 DOI: 10.1016/j.jacl.2019.11.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 18.3] [Reference Citation Analysis]
341 Casey DE Jr, Thomas RJ, Bhalla V, Commodore-Mensah Y, Heidenreich PA, Kolte D, Muntner P, Smith SC Jr, Spertus JA, Windle JR, Wozniak GD, Ziaeian B. 2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes 2019;12:e000057. [PMID: 31714813 DOI: 10.1161/HCQ.0000000000000057] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
342 Genest J, Nguyen DV. The Cat Has 9 Lives, Until it Dies. J Am Coll Cardiol 2019;73:397-9. [PMID: 30704570 DOI: 10.1016/j.jacc.2018.11.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
343 Trinder M, Walley KR, Boyd JH, Brunham LR. Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. Arterioscler Thromb Vasc Biol 2020;40:267-78. [PMID: 31694394 DOI: 10.1161/ATVBAHA.119.313381] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 17.3] [Reference Citation Analysis]
344 Sun CJ, McCudden C, Brisson D, Shaw J, Gaudet D, Ooi TC. Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. J Endocr Soc 2020;4:bvz010. [PMID: 32010872 DOI: 10.1210/jendso/bvz010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
345 Barry AR, Wang EH, Chua D, Pearson GJ. Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. CJC Open 2019;1:297-304. [DOI: 10.1016/j.cjco.2019.09.001] [Reference Citation Analysis]
346 Wen C, Metcalfe A, Anderson TJ, Johnson J, Sigal RJ, Nerenberg KA. Measurement of lipid profiles in the early postpartum period after hypertensive disorders of pregnancy. Journal of Clinical Lipidology 2019;13:1008-15. [DOI: 10.1016/j.jacl.2019.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Marquardt AR, Lewandowski KR, Paton CM, Cooper JA. Comparison of metabolic and antioxidant responses to a breakfast meal with and without pecans. Journal of Functional Foods 2019;62:103559. [DOI: 10.1016/j.jff.2019.103559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
348 Ko DT, Chu A, Austin PC, Johnston S, Nallamothu BK, Roifman I, Tusevljak N, Udell JA, Frank E. Comparison of Cardiovascular Risk Factors and Outcomes Among Practicing Physicians vs the General Population in Ontario, Canada. JAMA Netw Open 2019;2:e1915983. [PMID: 31755946 DOI: 10.1001/jamanetworkopen.2019.15983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
349 Terada T, Chirico D, Tulloch HE, Scott K, Pipe AL, Reed JL. Sex differences in psychosocial and cardiometabolic health among patients completing cardiac rehabilitation. Appl Physiol Nutr Metab 2019;44:1237-45. [DOI: 10.1139/apnm-2018-0876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
350 Viguiliouk E, Glenn AJ, Nishi SK, Chiavaroli L, Seider M, Khan T, Bonaccio M, Iacoviello L, Mejia SB, Jenkins DJA, Kendall CWC, Kahleová H, Rahelić D, Salas-Salvadó J, Sievenpiper JL. Associations between Dietary Pulses Alone or with Other Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Adv Nutr 2019;10:S308-19. [PMID: 31728500 DOI: 10.1093/advances/nmz113] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 15.0] [Reference Citation Analysis]
351 Horodinschi RN, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with Statins in Elderly Patients. Medicina (Kaunas) 2019;55:E721. [PMID: 31671689 DOI: 10.3390/medicina55110721] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
352 Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol 2019;10:401-8. [PMID: 31656566 DOI: 10.1136/flgastro-2018-101124] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
353 Loewen OK, Ekwaru JP, Ohinmmaa A, Veugelers PJ. Economic Burden of Not Complying with Canadian Food Recommendations in 2018. Nutrients 2019;11:E2529. [PMID: 31635176 DOI: 10.3390/nu11102529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
354 Darras P, Mattman A, Francis GA. Nonfasting lipid testing: the new standard for cardiovascular risk assessment. CMAJ 2018;190:E1317-8. [PMID: 30420386 DOI: 10.1503/cmaj.180804] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
355 Alvarez E, Qutob M, Mbuagbaw L, Lavis J, Lokker C, Walli-Attaei M, Samaan Z, Sutton A, Singh J, Feeny D, Fortuna J. Feasibility and implementation of a healthy lifestyles program in a community setting in Ontario, Canada: protocol for a pragmatic mixed methods pilot study. BMJ Open 2019;9:e031298. [PMID: 31619429 DOI: 10.1136/bmjopen-2019-031298] [Reference Citation Analysis]
356 Wen C, Metcalfe A, Anderson T, Sigal RJ, Johnson JA, Carson M, Nerenberg KA. Risks of Dysglycemia Over the First 4 Years After a Hypertensive Disorder of Pregnancy. Can J Diabetes 2019;43:587-93. [PMID: 31585793 DOI: 10.1016/j.jcjd.2019.07.150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. Arch Med Res 2019;50:285-94. [PMID: 31593853 DOI: 10.1016/j.arcmed.2019.08.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
358 Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA 2019;322:1294-304. [PMID: 31573641 DOI: 10.1001/jama.2019.14745] [Cited by in Crossref: 339] [Cited by in F6Publishing: 365] [Article Influence: 113.0] [Reference Citation Analysis]
359 Tobe SW, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou SS, Ezekowitz JA, Gregoire JC, Gubitz G, Jain R, Keshavjee K, Lindsay P, L'Abbe M, Lau DCW, Leiter LA, O'Meara E, Pearson GJ, Rabi DM, Sherifali D, Selby P, Tu JV, Wharton S, Walker KM, Hua-Stewart D, Liu PP. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. CMAJ 2018;190:E1192-206. [PMID: 30301743 DOI: 10.1503/cmaj.180194] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
360 Zhou H, Zhang S, Sun X, Yang D, Zhuang X, Guo Y, Hu X, Du Z, Zhang M, Liao X. Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation II-clinical practice guideline appraisal for lipid management in coronary heart disease. J Thorac Dis 2019;11:3534-46. [PMID: 31559060 DOI: 10.21037/jtd.2019.07.71] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
361 Manuel DG, Tuna M, Bennett C, Hennessy D, Rosella L, Sanmartin C, Tu JV, Perez R, Fisher S, Taljaard M. Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT). CMAJ 2018;190:E871-82. [PMID: 30037888 DOI: 10.1503/cmaj.170914] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
362 Côté CE, Rhéaume C, Poirier P, Després JP, Alméras N. Deteriorated Cardiometabolic Risk Profile in Individuals With Excessive Blood Pressure Response to Submaximal Exercise. Am J Hypertens 2019;32:945-52. [PMID: 31136645 DOI: 10.1093/ajh/hpz087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
363 Jaspers NEM, Ridker PM, Dorresteijn JAN, Visseren FLJ. The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. Curr Opin Lipidol 2018;29:436-44. [PMID: 30234556 DOI: 10.1097/MOL.0000000000000554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
364 Ference BA, Graham I, Tokgozoglu L, Catapano AL. Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:2980-95. [PMID: 30522632 DOI: 10.1016/j.jacc.2018.10.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
365 Kelly L, Matsumoto CL, Schreiber Y, Gordon J, Willms H, Olivier C, Madden S, Hopko J, Tobe SW. Prevalence of chronic kidney disease and cardiovascular comorbidities in adults in First Nations communities in northwest Ontario: a retrospective observational study. CMAJ Open 2019;7:E568-72. [PMID: 31501170 DOI: 10.9778/cmajo.20190040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
366 Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol 2018;72:434-47. [PMID: 30025580 DOI: 10.1016/j.jacc.2018.05.027] [Cited by in Crossref: 373] [Cited by in F6Publishing: 394] [Article Influence: 124.3] [Reference Citation Analysis]
367 Sobchak C, Akhtari S, Harvey P, Gladman D, Chandran V, Cook R, Eder L. Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. Arthritis Rheumatol 2019;71:1651-9. [PMID: 31165591 DOI: 10.1002/art.40925] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
368 Lozano-montoya I, Formiga F. Tratamiento con estatinas en los pacientes de más edad en 2018: cuándo, cómo y por qué. Revista Española de Geriatría y Gerontología 2019;54:249-250. [DOI: 10.1016/j.regg.2019.06.001] [Reference Citation Analysis]
369 Liu X, Yang Y, Kang F, Li J, Zhou M, Ma X, Yu T, Zhang T, Xue F. Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status. Am J Cardiol 2019;124:702-8. [PMID: 31311663 DOI: 10.1016/j.amjcard.2019.05.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
370 Dayan N, Udell JA. Moving Toward Sex-Specific Cardiovascular Risk Estimation. Can J Cardiol 2020;36:13-5. [PMID: 31740168 DOI: 10.1016/j.cjca.2019.08.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
371 Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 2018;14:727-49. [PMID: 30361677 DOI: 10.1038/s41581-018-0072-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 32.3] [Reference Citation Analysis]
372 Mason AE, Saslow LR, Moran PJ, Kim S, Abousleiman H, Richler R, Schleicher S, Goldman VM, Hartman A, Leung C, Hartogensis W, Hecht FM. Lipid findings from the Diabetes Education to Lower Insulin, Sugars, and Hunger (DELISH) Study. Nutr Metab (Lond) 2019;16:58. [PMID: 31467583 DOI: 10.1186/s12986-019-0383-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
373 Liu J, Dai Y, Yuan E, Li Y, Wang Q, Wang L, Su Y. Age-specific and sex-specific reference intervals for non-fasting lipids and apolipoproteins in 7260 healthy Chinese children and adolescents measured with an Olympus AU5400 analyser: a cross-sectional study. BMJ Open 2019;9:e030201. [PMID: 31427336 DOI: 10.1136/bmjopen-2019-030201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
374 Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP). The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol 2018;72:96-118. [PMID: 29957236 DOI: 10.1016/j.jacc.2018.04.040] [Cited by in Crossref: 170] [Cited by in F6Publishing: 180] [Article Influence: 56.7] [Reference Citation Analysis]
375 Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev 2019;40:537-57. [PMID: 30312399 DOI: 10.1210/er.2018-00184] [Cited by in Crossref: 133] [Cited by in F6Publishing: 143] [Article Influence: 44.3] [Reference Citation Analysis]
376 Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:104-14. [DOI: 10.1093/ehjcvp/pvz033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
377 Lafrenière J, Harrison S, Laurin D, Brisson C, Talbot D, Couture P, Lemieux S, Lamarche B. Development and validation of a Brief Diet Quality Assessment Tool in the French-speaking adults from Quebec. Int J Behav Nutr Phys Act 2019;16:61. [PMID: 31387609 DOI: 10.1186/s12966-019-0821-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
378 Simard T, Jung R, Labinaz A, Faraz MA, Ramirez FD, Di Santo P, Perry-Nguyen D, Pitcher I, Motazedian P, Gaudet C, Rochman R, Marbach J, Boland P, Sarathy K, Alghofaili S, Russo JJ, Couture E, Promislow S, Beanlands RS, Hibbert B. Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations. J Am Heart Assoc 2019;8:e012228. [PMID: 31379241 DOI: 10.1161/JAHA.119.012228] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
379 Mello e Silva A, Aguiar C, Sequeira Duarte J, Couto L, Teixeira Veríssimo M, Marques da Silva P. CODAP: um consenso multidisciplinar sobre a definição, diagnóstico e tratamento da dislipidemia aterogénica em Portugal. Revista Portuguesa de Cardiologia 2019;38:531-542. [DOI: 10.1016/j.repc.2019.03.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Mello e Silva A, Aguiar C, Duarte JS, Couto L, Veríssimo MT, da Silva PM. CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. Revista Portuguesa de Cardiologia (English Edition) 2019;38:531-542. [DOI: 10.1016/j.repce.2019.03.010] [Reference Citation Analysis]
381 Gladstone RA, Pudwell J, Nerenberg KA, Grover SA, Smith GN. Cardiovascular Risk Assessment and Follow-Up of Women After Hypertensive Disorders of Pregnancy:A Prospective Cohort Study. Journal of Obstetrics and Gynaecology Canada 2019;41:1157-1167.e1. [DOI: 10.1016/j.jogc.2018.10.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
382 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-miranda J, Tybjærg-hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. CVP 2019;17:515-37. [DOI: 10.2174/1570161117666190503123911] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
383 Vasquez N, Joshi PH. Lp(a): Addressing a Target for Cardiovascular Disease Prevention. Curr Cardiol Rep 2019;21:102. [PMID: 31367887 DOI: 10.1007/s11886-019-1182-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
384 Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C, Healey JS, Bell A, Cairns J, Connolly S, Cox J, Dorian P, Gladstone D, McMurtry MS, Nair GM, Pilote L, Sarrazin JF, Sharma M, Skanes A, Talajic M, Tsang T, Verma S, Wyse DG, Nattel S, Macle L; CCS Atrial Fibrillation Guidelines Committee. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2018;34:1371-92. [PMID: 30404743 DOI: 10.1016/j.cjca.2018.08.026] [Cited by in Crossref: 161] [Cited by in F6Publishing: 170] [Article Influence: 53.7] [Reference Citation Analysis]
385 Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Paré G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol 2018;34:1553-63. [PMID: 30527143 DOI: 10.1016/j.cjca.2018.09.005] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 22.7] [Reference Citation Analysis]
386 Liu S, Wu N, Guo Y, Zhu C, Gao Y, Sun J, Xu R, Liu G, Dong Q, Li J. Lipoprotein(a) and coronary artery disease in Chinese postmenopausal female patients: a large cross-sectional cohort study. Postgrad Med J 2019;95:534-40. [DOI: 10.1136/postgradmedj-2019-136591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
387 Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. J Am Coll Cardiol 2018;71:794-9. [PMID: 29447742 DOI: 10.1016/j.jacc.2017.12.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
388 Hai JJ, Wong YK, Wong CK, Un KC, Chan PH, Siu CW, Yiu KH, Lau CP, Tse HF. Prognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin. BMC Cardiovasc Disord 2019;19:168. [PMID: 31307391 DOI: 10.1186/s12872-019-1152-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
389 Panafidina TA, Popkova TV, Solovyev SK. Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). Naučno-praktičeskaâ revmatologiâ 2019;57:255-264. [DOI: 10.14412/1995-4484-2019-255-264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
390 Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol 2018;71:177-92. [PMID: 29325642 DOI: 10.1016/j.jacc.2017.11.014] [Cited by in Crossref: 230] [Cited by in F6Publishing: 242] [Article Influence: 76.7] [Reference Citation Analysis]
391 Vikulova DN, Grubisic M, Zhao Y, Lynch K, Humphries KH, Pimstone SN, Brunham LR. Premature Atherosclerotic Cardiovascular Disease: Trends in Incidence, Risk Factors, and Sex-Related Differences, 2000 to 2016. J Am Heart Assoc 2019;8:e012178. [PMID: 31280642 DOI: 10.1161/JAHA.119.012178] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 13.0] [Reference Citation Analysis]
392 Chen G, Farris MS, Cowling T, Colgan SM, Xiang P, Pericleous L, Rogoza RM, Tai M, Anderson T. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology 2019;35:884-91. [DOI: 10.1016/j.cjca.2019.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
393 Kolovou G, Giannakopoulou V, Kalogeropoulos P, Anagnostopoulou K, Goumas G, Kazianis G, Limberi S, Perrea D, Mihas C, Kolovou V, Bilianou H. Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. Contemporary Clinical Trials 2019;82:101-5. [DOI: 10.1016/j.cct.2019.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
394 Jenkins DJA, Blanco Mejia S, Chiavaroli L, Viguiliouk E, Li SS, Kendall CWC, Vuksan V, Sievenpiper JL. Cumulative Meta-Analysis of the Soy Effect Over Time. J Am Heart Assoc 2019;8:e012458. [PMID: 31242779 DOI: 10.1161/JAHA.119.012458] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
395 Su X, Luo M, Tang X, Luo Y, Zheng X, Peng D; CCC-ACS Investigators. Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. Clin Chim Acta 2019;496:48-54. [PMID: 31255567 DOI: 10.1016/j.cca.2019.06.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
396 Houben E, Mendel A, van der Heijden JW, Simsek S, Bax WA, Carette S, Voskuyl AE, Pagnoux C, Penne EL. Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. Rheumatology 2019;58:2333-5. [DOI: 10.1093/rheumatology/kez229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
397 Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. High Blood Press Cardiovasc Prev 2019;26:199-207. [PMID: 31236902 DOI: 10.1007/s40292-019-00323-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
398 Glenn AJ, Viguiliouk E, Seider M, Boucher BA, Khan TA, Blanco Mejia S, Jenkins DJA, Kahleová H, Rahelić D, Salas-Salvadó J, Kendall CWC, Sievenpiper JL. Relation of Vegetarian Dietary Patterns With Major Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Front Nutr 2019;6:80. [PMID: 31263700 DOI: 10.3389/fnut.2019.00080] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
399 Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou EN, Yannakoulia M, Tousoulis D, Pitsavos C. Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. Angiology 2019;70:819-29. [DOI: 10.1177/0003319719854872] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
400 Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis 2019;18:134. [PMID: 31170997 DOI: 10.1186/s12944-019-1080-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
401 Alothman L, Zawadka M, Aljenedil S, Kajil M, Bewick D, Gaudet D, Hegele RA, Lonn E, Ngui D, Ruel I, Tsigoulis M, Singh N, Genest J, Gupta M. Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC Open 2019;1:190-7. [PMID: 32159106 DOI: 10.1016/j.cjco.2019.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
402 Gladstone RA, Pudwell J, Pal RS, Smith GN. Referral to Cardiology Following Postpartum Cardiovascular Risk Screening at the Maternal Health Clinic in Kingston, Ontario. Can J Cardiol 2019;35:761-9. [PMID: 31151712 DOI: 10.1016/j.cjca.2019.03.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
403 Yandrapalli S, Gupta S, Andries G, Cooper HA, Aronow WS. Drug Therapy of Dyslipidemia in the Elderly. Drugs Aging 2019;36:321-40. [PMID: 30613912 DOI: 10.1007/s40266-018-00632-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
404 Dayan N, Nerenberg K. Postpartum Cardiovascular Prevention: The Need for a National Health Systems-Based Strategy. Canadian Journal of Cardiology 2019;35:701-4. [DOI: 10.1016/j.cjca.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
405 Desgagné V, Guérin R, Guay SP, Boyer M, Hutchins E, Picard S, Maréchal A, Corbin F, Keuren-Jensen KV, Arsenault BJ, Bouchard L. Human high-density lipoprotein microtranscriptome is unique and suggests an extended role in lipid metabolism. Epigenomics 2019;11:917-34. [PMID: 31144512 DOI: 10.2217/epi-2018-0161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
406 Lin QZ, Chen YQ, Guo LL, Xiang QY, Tian F, Wen T, Liu L. Comparison of non-fasting LDL-C levels calculated by Friedewald formula with those directly measured in Chinese patients with coronary heart disease after a daily breakfast. Clin Chim Acta 2019;495:399-405. [PMID: 31085187 DOI: 10.1016/j.cca.2019.05.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
407 Fitchett D. To Risk Stratify or Not for Statin Therapy. Canadian Journal of Cardiology 2019;35:550-551. [DOI: 10.1016/j.cjca.2019.01.009] [Reference Citation Analysis]
408 Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, Mcneal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology 2019;13:374-92. [DOI: 10.1016/j.jacl.2019.04.010] [Cited by in Crossref: 188] [Cited by in F6Publishing: 202] [Article Influence: 62.7] [Reference Citation Analysis]
409 Dubrofsky L, Tobe SW. Guideline Alignment in Related Areas. Canadian Journal of Cardiology 2019;35:606-610. [DOI: 10.1016/j.cjca.2019.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
410 Thanassoulis G, Gregoire J, Pearson GJ. The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian? Can J Cardiol 2019;35:558-63. [PMID: 31030858 DOI: 10.1016/j.cjca.2019.03.003] [Reference Citation Analysis]
411 Khunti K, Jung H, Dans AL, Held C, Dagenais GR, Yusuf S, Lonn E. Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. Can J Cardiol 2019;35:644-52. [PMID: 31030865 DOI: 10.1016/j.cjca.2019.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
412 Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, Karia K, Panguluri SK. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis 2019;6:E19. [PMID: 31035613 DOI: 10.3390/jcdd6020019] [Cited by in Crossref: 156] [Cited by in F6Publishing: 173] [Article Influence: 52.0] [Reference Citation Analysis]
413 Dar T, Radfar A, Abohashem S, Pitman RK, Tawakol A, Osborne MT. Psychosocial Stress and Cardiovascular Disease. Curr Treat Options Cardiovasc Med 2019;21:23. [PMID: 31028483 DOI: 10.1007/s11936-019-0724-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 18.3] [Reference Citation Analysis]
414 Huang A, Qi X, Wei L, Zhang M, Zhou S. Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes. Cardiol Res Pract 2019;2019:5931975. [PMID: 31179126 DOI: 10.1155/2019/5931975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
415 He B, Moreau R. Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications. Pharmacol Res 2019;144:116-31. [PMID: 30954630 DOI: 10.1016/j.phrs.2019.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
416 Ellis KL, Chakraborty A, Moses EK, Watts GF. To test, or not to test: that is the question for the future of lipoprotein(a). Expert Rev Cardiovasc Ther 2019;17:241-50. [PMID: 30916582 DOI: 10.1080/14779072.2019.1596799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
417 Wang J, Jia L, Li X, Jin S, Li X, Liu F, Shan C, Zhang Y, Yang Y. New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study. Cardiovasc Ther 2019;2019:8563717. [PMID: 31772619 DOI: 10.1155/2019/8563717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
418 Djordjevic DB, Dordevic AD, Lovic DB. Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. Curr Pharmacol Rep 2019;5:87-97. [DOI: 10.1007/s40495-019-00173-w] [Reference Citation Analysis]
419 Liu R, Cheng J, Muzlera C, Robinson JF, Ban MR, Hegele RA. Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score. CJC Open 2019;1:69-75. [PMID: 32159086 DOI: 10.1016/j.cjco.2019.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
420 Solah VA, Kerr DA, Irawati D, Hunt W, Meng X, Gahler RJ, Fenton HK, Johnson SK, James AP, Wood S. Effect of PolyGlycopleX (PGX) Consumption on Blood Lipid Profiles in Healthy, Low CVD Risk Overweight Adults. Nutrients 2019;11:E717. [PMID: 30934797 DOI: 10.3390/nu11040717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
421 Renee Ruhaak L, van der Laarse A, Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Ann Clin Biochem 2019;56:338-56. [PMID: 30889974 DOI: 10.1177/0004563219827620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
422 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:e177-232. [PMID: 30894318 DOI: 10.1016/j.jacc.2019.03.010] [Cited by in Crossref: 629] [Cited by in F6Publishing: 700] [Article Influence: 209.7] [Reference Citation Analysis]
423 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-646. [PMID: 30879355 DOI: 10.1161/CIR.0000000000000678] [Cited by in Crossref: 513] [Cited by in F6Publishing: 834] [Article Influence: 171.0] [Reference Citation Analysis]
424 Wang TJ, Lien AS, Chen JL, Lin CH, Yang YS, Yang SH. A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia. Am J Chin Med 2019;47:323-35. [PMID: 30871361 DOI: 10.1142/S0192415X19500150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
425 Faraj M. Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l’apoB athérogènes dans l’étiologie du diabète de type 2. Médecine des Maladies Métaboliques 2019;13:129-139. [DOI: 10.1016/s1957-2557(19)30042-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Marushka L, Kenny TA, Batal M, Cheung WWL, Fediuk K, Golden CD, Salomon AK, Sadik T, Weatherdon LV, Chan HM. Potential impacts of climate-related decline of seafood harvest on nutritional status of coastal First Nations in British Columbia, Canada. PLoS One 2019;14:e0211473. [PMID: 30811408 DOI: 10.1371/journal.pone.0211473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
427 Hammad MA, Syed Sulaiman SA, Aziz NA, Mohamed Noor DA. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. J Res Med Sci 2019;24:15. [PMID: 30988683 DOI: 10.4103/jrms.JRMS_100_18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
428 Cardoso R, Blumenthal RS, Kopecky S, Lopez-Jimenez F, Martin SS. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clin Proc 2019;94:660-9. [PMID: 30737057 DOI: 10.1016/j.mayocp.2018.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
429 Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients 2019;11:E338. [PMID: 30764511 DOI: 10.3390/nu11020338] [Cited by in Crossref: 174] [Cited by in F6Publishing: 180] [Article Influence: 58.0] [Reference Citation Analysis]
430 Jun JE, Cho IJ, Han K, Jeong IK, Ahn KJ, Chung HY, Hwang YC. Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. Atherosclerosis 2019;283:28-34. [PMID: 30772771 DOI: 10.1016/j.atherosclerosis.2019.01.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
431 Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Ther Clin Risk Manag 2019;15:137-45. [PMID: 30705590 DOI: 10.2147/TCRM.S182716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
432 Raggi P, Senior P, Shahbaz S, Kaul P, Hung R, Coulden R, Yeung RO, Abele J. 18 F-Sodium Fluoride Imaging of Coronary Atherosclerosis in Ambulatory Patients With Diabetes Mellitus. ATVB 2019;39:276-84. [DOI: 10.1161/atvbaha.118.311711] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
433 Vuorio A, Watts GF, Kovanen PT. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis 2019;281:25-30. [DOI: 10.1016/j.atherosclerosis.2018.11.040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
434 Hadjiphilippou S, Ray KK. Cholesterol-Lowering Agents: Statins—For Everyone? Circ Res 2019;124:354-63. [DOI: 10.1161/circresaha.118.313245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
435 Hong W, Zimmer V, Basharat Z, Zippi M, Stock S, Geng W, Bao X, Dong J, Pan J, Zhou M. Association of total cholesterol with severe acute pancreatitis: A U-shaped relationship. Clin Nutr 2020;39:250-7. [PMID: 30772093 DOI: 10.1016/j.clnu.2019.01.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
436 Bartlomiejczyk MA, Penson P, Banach M. Worldwide Dyslipidemia Guidelines. Curr Cardiovasc Risk Rep 2019;13. [DOI: 10.1007/s12170-019-0597-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
437 Gobis B, Kapanen AI, Reardon J, Min J, Li KH, Lynd LD, Zed PJ. Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site). Ann Pharmacother 2019;53:574-80. [DOI: 10.1177/1060028018823330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
438 Zheng J, Sun Z, Zhang X, Li Z, Guo X, Xie Y, Sun Y, Zheng L. Non-traditional lipid profiles associated with ischemic stroke not hemorrhagic stroke in hypertensive patients: results from an 8.4 years follow-up study. Lipids Health Dis 2019;18:9. [PMID: 30621696 DOI: 10.1186/s12944-019-0958-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
439 Li G, Zhou L, Ouyang W, Xuan M, Lu L, Li X, Wen Z, Chen X. A core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey. Trials 2019;20:14. [PMID: 30612586 DOI: 10.1186/s13063-018-3082-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
440 Noel A, Genest J. Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. Can J Cardiol 2019;35:17-8. [PMID: 30595177 DOI: 10.1016/j.cjca.2018.11.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Sievenpiper JL, Riccardi G, Ricordi C, Dembska K. Nutrition, Health and Dietary Trends. Achieving the Sustainable Development Goals Through Sustainable Food Systems 2019. [DOI: 10.1007/978-3-030-23969-5_4] [Reference Citation Analysis]
442 Zaitoun MF, Iflaifel MH, Almulhim LA, Al-Ghamdi MA, Ibrahim YA. Awareness of Physicians and Clinical Pharmacists About ACC/AHA Guidelines for Dyslipidemia Management: A Cross-Sectional Study. J Pharm Bioallied Sci 2019;11:181-6. [PMID: 31148896 DOI: 10.4103/jpbs.JPBS_59_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
443 Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-dinet MT, Din-bell C, Manvelian G, Farnier M. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. Journal of Clinical Lipidology 2019;13:138-47. [DOI: 10.1016/j.jacl.2018.11.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
444 Subramanian S, Chait A. Dyslipidemia in Diabetes. Encyclopedia of Endocrine Diseases 2019. [DOI: 10.1016/b978-0-12-801238-3.65798-7] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
445 Hanboly N, Sharaf Y, Al-anany M, Saeed E. Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease. Nig J Cardiol 2019;16:25. [DOI: 10.4103/njc.njc_20_18] [Reference Citation Analysis]
446 Villar JC, Bermudez PA. Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in the Midst of Uncertainty. Chagas Disease 2019. [DOI: 10.1007/978-3-030-00054-7_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
447 Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology 2019;51:148-54. [PMID: 30595507 DOI: 10.1016/j.pathol.2018.11.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
448 Sicras-Mainar A, Sánchez-Álvarez L, Navarro-Artieda R, Darbà J. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis. Lipids Health Dis 2018;17:277. [PMID: 30522491 DOI: 10.1186/s12944-018-0918-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
449 Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology 2019;51:131-41. [PMID: 30522787 DOI: 10.1016/j.pathol.2018.09.062] [Cited by in Crossref: 84] [Cited by in F6Publishing: 90] [Article Influence: 21.0] [Reference Citation Analysis]
450 Brassard D, Laramée C, Corneau L, Bégin C, Bélanger M, Bouchard L, Couillard C, Desroches S, Houle J, Langlois M, Provencher V, Rabasa-lhoret R, Vohl M, Robitaille J, Lemieux S, Lamarche B. Poor Adherence to Dietary Guidelines Among French-Speaking Adults in the Province of Quebec, Canada: The PREDISE Study. Canadian Journal of Cardiology 2018;34:1665-73. [DOI: 10.1016/j.cjca.2018.09.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
451 Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. Canadian Journal of Cardiology 2018;34:1600-5. [DOI: 10.1016/j.cjca.2018.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
452 Lyngbakken MN, Myhre PL, Røsjø H, Omland T. Novel biomarkers of cardiovascular disease: Applications in clinical practice. Critical Reviews in Clinical Laboratory Sciences 2019;56:33-60. [DOI: 10.1080/10408363.2018.1525335] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
453 Mitchell D, Guertin JR, Dubois A, Dubé MP, Tardif JC, Iliza AC, Fanton-Aita F, Matteau A, LeLorier J. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Mol Diagn Ther 2018;22:241-54. [PMID: 29651791 DOI: 10.1007/s40291-018-0323-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
454 Wolever TM, Augustin LS, Brand-Miller JC, Delport E, Livesey G, Ludwig DS, Sievenpiper JL. Glycemic index is as reliable as macronutrients on food labels. Am J Clin Nutr. 2017;105:768-769. [PMID: 28251938 DOI: 10.3945/ajcn.116.146092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
455 Lan NSR, Fegan PG, Yeap BB, Bell DA, Watts GF. Dyslipidaemia in adults with type 1 diabetes-when to treat? Diabetes Metab Res Rev 2019;35:e3090. [PMID: 30339719 DOI: 10.1002/dmrr.3090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
456 Higgins V, Asgari S, Chan M, Adeli K. Pediatric reference intervals for calculated LDL cholesterol, non-HDL cholesterol, and remnant cholesterol in the healthy CALIPER cohort. Clinica Chimica Acta 2018;486:129-34. [DOI: 10.1016/j.cca.2018.07.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
457 Aldasouqi S, Mora S, Bhalla G, Kakumanu N, Corser W, Abela G, Dlewati M, Estrada K, Almounajed A, Tabbaa T, Hammoud J, Newkirk C. Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. Int J Endocrinol 2018;2018:1528437. [PMID: 30473710 DOI: 10.1155/2018/1528437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
458 da Silva PM, Duarte JS, von Hafe P, Gil V, de Oliveira JN, de Sousa G. Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report. Atheroscler Suppl 2018;31:e1-e12. [PMID: 29859563 DOI: 10.1016/j.atherosclerosissup.2018.04.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
459 Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol 2018;41:1328-35. [PMID: 30120772 DOI: 10.1002/clc.23049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
460 Mancini GBJ, Cheng AY, Connelly K, Fitchett D, Goldenberg R, Goodman S, Leiter LA, Lonn E, Paty B, Poirier P, Stone J, Thompson D, Verma S, Woo V, Yale J. CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Canadian Journal of Cardiology 2018;34:1350-61. [DOI: 10.1016/j.cjca.2018.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
461 Watts GF, Boffa MB. Lipoprotein(a): lodestar for future clinical trials. The Lancet 2018;392:1281-2. [DOI: 10.1016/s0140-6736(18)31922-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
462 Ellis KL, Watts GF. Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic? Cardiol Clin 2018;36:287-98. [PMID: 29609758 DOI: 10.1016/j.ccl.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
463 Hadjiphilippou S, Ray KK. Lipids and Lipoproteins in Risk Prediction. Cardiol Clin 2018;36:213-20. [PMID: 29609750 DOI: 10.1016/j.ccl.2017.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
464 Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, Li D, Sievenpiper J, Duvnjak L, Vuksan V. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition 2018;108:922-32. [DOI: 10.1093/ajcn/nqy115] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
465 Mitchell D, Guertin JR, Lelorier J. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Mol Diagn Ther 2018;22:641-52. [DOI: 10.1007/s40291-018-0356-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
466 Pallazola VA, Quispe R, Elshazly MB, Vakil R, Sathiyakumar V, Jones SR, Martin SS. Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. Curr Cardiovasc Risk Rep 2018;12. [DOI: 10.1007/s12170-018-0590-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
467 Tmojan NA, Afanasieva ОI, Zotikov AЕ, Klesareva EA, Abdulgamidov MM, Ezhov МV, Pokrovsky AV, Pokrovsky SN. RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER ExTREMETIES ARTERIES. Russ J Cardiol 2018. [DOI: 10.15829/1560-4071-2018-8-7-12] [Reference Citation Analysis]
468 Trautwein EA, Vermeer MA, Hiemstra H, Ras RT. LDL-Cholesterol Lowering of Plant Sterols and Stanols-Which Factors Influence Their Efficacy? Nutrients 2018;10:E1262. [PMID: 30205492 DOI: 10.3390/nu10091262] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
469 Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology 2018;12:1313-23. [DOI: 10.1016/j.jacl.2018.07.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
470 Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol 2018;45:1426-39. [PMID: 30173152 DOI: 10.3899/jrheum.171459] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
471 Mcpherson R. The Cardiovascular Burden of Undiagnosed Familial Hypercholesterolemia: Need to Modify Guidelines to Encourage Earlier Diagnosis and Therapy. Canadian Journal of Cardiology 2018;34:1112-3. [DOI: 10.1016/j.cjca.2018.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
472 Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology 2018;72:1141-56. [DOI: 10.1016/j.jacc.2018.06.046] [Cited by in Crossref: 166] [Cited by in F6Publishing: 176] [Article Influence: 41.5] [Reference Citation Analysis]
473 Serrano OK, Bangdiwala AS, Vock DM, Chinnakotla S, Dunn TB, Finger EB, Kandaswamy R, Pruett TL, Najarian JS, Matas AJ, Chavers B. Incidence and magnitude of post-transplant cardiovascular disease after pediatric kidney transplantation: Risk factor analysis of 1058 pediatric kidney transplants at the university of Minnesota. Pediatr Transplant 2018;22:e13283. [PMID: 30151948 DOI: 10.1111/petr.13283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
474 Langlois MR, Nordestgaard BG. Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias? Curr Cardiol Rep 2018;20:88. [PMID: 30120626 DOI: 10.1007/s11886-018-1036-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
475 Waters DD. Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. Can J Cardiol 2019;35:590-7. [PMID: 30454967 DOI: 10.1016/j.cjca.2018.07.477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
476 Razek O, Cermakova L, Armani H, Lee T, Francis GA, Mancini GJ, Frohlich J, Brunham LR. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. Canadian Journal of Cardiology 2018;34:1004-9. [DOI: 10.1016/j.cjca.2018.04.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
477 Baass A, Hegele RA. Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia. Canadian Journal of Cardiology 2018;34:959-61. [DOI: 10.1016/j.cjca.2018.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
478 Ray JG, Huang T, Meschino WS, Cohen E, Park AL. Prenatal biochemical screening and long term risk of maternal cardiovascular disease: population based cohort study. BMJ 2018;362:k2739. [PMID: 29997198 DOI: 10.1136/bmj.k2739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
479 Sanchez Muñoz-Torrero JF, Rico-Martín S, Álvarez LR, Aguilar E, Alcalá JN, Monreal M; FRENA Investigators. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis 2018;276:10-4. [PMID: 30006322 DOI: 10.1016/j.atherosclerosis.2018.07.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
480 Brito FA, Pedrosa W, Maluf CB, dos Reis RC, Fedeli LM, Castilhos C, Barreto SM, Vidigal PG. Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: Is it time to change? Atherosclerosis 2018;274:243-50. [DOI: 10.1016/j.atherosclerosis.2018.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
481 Turgeon RD, Pearson GJ. Comment: Should an LDL Cholesterol Target–Based Approach Be Readopted? Ann Pharmacother 2018;52:706-707. [DOI: 10.1177/1060028018765941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
482 Stock JK. Navigating the highlights of EAS Congress Lisbon. Atherosclerosis 2018;275:387-9. [PMID: 29945722 DOI: 10.1016/j.atherosclerosis.2018.06.003] [Reference Citation Analysis]
483 Schmidt TJ, Aviña-zubieta JA, Sayre EC, Abrahamowicz M, Esdaile JM, Lacaille D. Quality of care for cardiovascular disease prevention in rheumatoid arthritis: compliance with hyperlipidemia screening guidelines. Rheumatology 2018;57:1789-94. [DOI: 10.1093/rheumatology/key164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
484 Jomphe V, Lands LC, Mailhot G. Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations. Nutrients 2018;10:E790. [PMID: 29921799 DOI: 10.3390/nu10060790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
485 Coutinho T, Lamai O, Nerenberg K. Hypertensive Disorders of Pregnancy and Cardiovascular Diseases: Current Knowledge and Future Directions. Curr Treat Options Cardio Med 2018;20. [DOI: 10.1007/s11936-018-0653-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
486 Brunham LR, Lynch K, English A, Sutherland R, Weng J, Cho R, Wong GC, Anis AH, Francis GA, Khan NA, McManus B, Wood D, Walley KR, Leipsic J, Humphries KH, Hoens A, Krahn AD, John Mancini GB, Pimstone S. The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. Clin Cardiol 2018;41:888-95. [PMID: 29635745 DOI: 10.1002/clc.22959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
487 Pandey AS, Bajaj HS, Garg V, Pandey A, Verma S. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. Curr Opin Cardiol 2017;32:633-41. [PMID: 28557865 DOI: 10.1097/HCO.0000000000000424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
488 Kivimäki M, Pentti J, Ferrie JE, Batty GD, Nyberg ST, Jokela M, Virtanen M, Alfredsson L, Dragano N, Fransson EI, Goldberg M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Luukkonen R, Oksanen T, Rugulies R, Siegrist J, Singh-Manoux A, Suominen S, Theorell T, Väänänen A, Vahtera J, Westerholm PJM, Westerlund H, Zins M, Strandberg T, Steptoe A, Deanfield J; IPD-Work consortium. Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study. Lancet Diabetes Endocrinol 2018;6:705-13. [PMID: 29884468 DOI: 10.1016/S2213-8587(18)30140-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 17.5] [Reference Citation Analysis]
489 Prince SA, Reid RD, Pipe AL, McDonnell LA. An evaluation of CardioPrevent: a technology-enabled, health-behavior change program for the global reduction of cardiovascular risk. Curr Opin Cardiol 2017;32:580-9. [PMID: 28639974 DOI: 10.1097/HCO.0000000000000438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
490 Cui FM, Fang F, He YM, Cai DP, He J, Yang XJ. Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction. Clin Chim Acta 2018;484:232-6. [PMID: 29883631 DOI: 10.1016/j.cca.2018.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
491 Turgeon RD, Pearson GJ. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. American Journal of Health-System Pharmacy 2018;75:747-54. [DOI: 10.2146/ajhp170707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
492 Zhang HW, Zhao X, Guo YL, Gao Y, Zhu CG, Wu NQ, Li JJ. Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2018;28:980-6. [PMID: 30030022 DOI: 10.1016/j.numecd.2018.05.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
493 Chiavaroli L, Nishi SK, Khan TA, Braunstein CR, Glenn AJ, Mejia SB, Rahelić D, Kahleová H, Salas-Salvadó J, Jenkins DJA, Kendall CWC, Sievenpiper JL. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. Prog Cardiovasc Dis 2018;61:43-53. [PMID: 29807048 DOI: 10.1016/j.pcad.2018.05.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 69] [Article Influence: 21.3] [Reference Citation Analysis]
494 Yebyo HG, Aschmann HE, Yu T, Puhan MA. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. BMC Cardiovasc Disord 2018;18:97. [PMID: 29776337 DOI: 10.1186/s12872-018-0838-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
495 Dai W, Long J, Cheng Y, Chen Y, Zhao S. Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. Sci Rep 2018;8:7726. [PMID: 29769559 DOI: 10.1038/s41598-018-25835-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
496 Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem 2018;64:1006-33. [PMID: 29760220 DOI: 10.1373/clinchem.2018.287037] [Cited by in Crossref: 130] [Cited by in F6Publishing: 136] [Article Influence: 32.5] [Reference Citation Analysis]
497 Alter DA, Tu JV, Koh M, Jackevicius CA, Austin PC, Rezai MR, Bhatia RS, Johnston S, Udell JA, Ko DT. Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. J Am Heart Assoc 2018;7:e007535. [PMID: 29754125 DOI: 10.1161/JAHA.117.007535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
498 Kelly SG, Krueger KM, Grant JL, Penugonda S, Feinstein MJ, Taiwo BO, Achenbach CJ. Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients. J Acquir Immune Defic Syndr 2017;76:e26-9. [PMID: 28520617 DOI: 10.1097/QAI.0000000000001454] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
499 Stahel P, Xiao C, Hegele RA, Lewis GF. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Canadian Journal of Cardiology 2018;34:595-604. [DOI: 10.1016/j.cjca.2017.12.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
500 Masi S, Taddei S, Virdis A. Statin guidelines: Friend or foes? Eur J Prev Cardiolog 2018;25:867-869. [DOI: 10.1177/2047487318768941] [Reference Citation Analysis]
501 Lieffers JRL, Ekwaru JP, Ohinmaa A, Veugelers PJ. The economic burden of not meeting food recommendations in Canada: The cost of doing nothing. PLoS One 2018;13:e0196333. [PMID: 29702680 DOI: 10.1371/journal.pone.0196333] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
502 da Silva PM, Sequeira Duarte J, von Hafe P, Gil V, Nunes de Oliveira J, de Sousa G. Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines - Executive summary: A consensus endorsed by the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, the Portuguese Atherosclerosis Society, the Portuguese Society of Cardiology, the Portuguese Society of Laboratory Medicine, and the Portuguese Association of Clinical Chemistry. Rev Port Cardiol (Engl Ed) 2018;37:279-83. [PMID: 29685846 DOI: 10.1016/j.repc.2017.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can Pharm J (Ott) 2018;151:179-88. [PMID: 29796131 DOI: 10.1177/1715163518768534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
504 Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The year in cardiology 2017: prevention. Cardiologia Croatica 2018;13:79-98. [DOI: 10.15836/ccar2018.79] [Reference Citation Analysis]
505 da Silva PM, Sequeira Duarte J, von Hafe P, Gil V, Nunes de Oliveira J, de Sousa G. Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines – Executive summary. Revista Portuguesa de Cardiologia (English Edition) 2018;37:279-283. [DOI: 10.1016/j.repce.2017.07.004] [Reference Citation Analysis]
506 Mancini GJ, Hegele RA, Leiter LA. Dyslipidemia. Canadian Journal of Diabetes 2018;42:S178-85. [DOI: 10.1016/j.jcjd.2017.10.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
507 Stone JA, Houlden RL, Lin P, Udell JA, Verma S. Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes 2018;42:S162-9. [DOI: 10.1016/j.jcjd.2017.10.024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
508 Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrieres J, Gitt AK. How does the TRS 2°P score relate to real-world patients? Eur Heart J Cardiovasc Pharmacother 2018;4:72-4. [PMID: 29554293 DOI: 10.1093/ehjcvp/pvy004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
509 Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams SL. Nutrition Therapy. Canadian Journal of Diabetes 2018;42:S64-79. [DOI: 10.1016/j.jcjd.2017.10.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 54] [Article Influence: 18.8] [Reference Citation Analysis]
510 Fang M, Qian Q, Zhao Z, Zhu L, Su J, Li X. High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. Int Heart J 2018;59:300-6. [PMID: 29479010 DOI: 10.1536/ihj.17-101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
511 Leening MJG, Ikram MA. Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments. PLoS Med 2018;15:e1002539. [PMID: 29558473 DOI: 10.1371/journal.pmed.1002539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
512 Makhatova A, Tuleutayeva R, Mussina A, Gorbatenko A. Pharmacoepidemiology of statins in Еast region of Kazakhstan. J CLIN MED KAZ 2018;1:36-40. [DOI: 10.23950/1812-2892-jcmk-00540] [Reference Citation Analysis]
513 Varbo A, Nordestgaard BG. Remnant lipoproteins. Curr Opin Lipidol 2017;28:300-7. [PMID: 28548974 DOI: 10.1097/MOL.0000000000000429] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
514 Sathiyakumar V, Park J, Quispe R, Elshazly MB, Michos ED, Banach M, Toth PP, Whelton SP, Blumenthal RS, Jones SR, Martin SS. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation 2018;138:244-54. [PMID: 29506984 DOI: 10.1161/CIRCULATIONAHA.117.032463] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
515 Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS. Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level? Clin Cardiol 2018;41:333-338. [DOI: 10.1002/clc.22868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
516 Kiburg KV, Ward GM, O'Neal DN, MacIsaac RJ. Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic. Intern Med J 2018;48:201-4. [PMID: 29415350 DOI: 10.1111/imj.13691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
517 Ruel I, Aljenedil S, Sadri I, de Varennes É, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, Brunham LR, Francis GA, Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry 2018;64:355-62. [DOI: 10.1373/clinchem.2017.279422] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
518 Cartier L, Collins C, Lagacé M, Douville P. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clinical Biochemistry 2018;52:61-6. [DOI: 10.1016/j.clinbiochem.2017.11.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
519 Shoveller AK, McKnight LM, Wood KM, Cant JP. Lessons from animal nutritionists: dietary amino acid requirement studies and considerations for healthy aging studies. Ann N Y Acad Sci 2018;1418:20-30. [PMID: 29363772 DOI: 10.1111/nyas.13546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
520 Katsiki N, Kolovou G, Perez-Martinez P, Mikhailidis DP. Dyslipidaemia in the elderly: to treat or not to treat? Expert Rev Clin Pharmacol 2018;11:259-78. [PMID: 29303009 DOI: 10.1080/17512433.2018.1425138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
521 Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The year in cardiology 2017: prevention. European Heart Journal 2018;39:345-53. [DOI: 10.1093/eurheartj/ehx766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
522 Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. Journal of the American College of Cardiology 2018;71:85-94. [DOI: 10.1016/j.jacc.2017.10.080] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 21.8] [Reference Citation Analysis]
523 Chan P, Shao L, Tomlinson B, Liu ZM. The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia. Ann Transl Med 2017;5:477. [PMID: 29285510 DOI: 10.21037/atm.2017.10.26] [Reference Citation Analysis]
524 Humphries KH, Pilote L. Research in Women's Cardiovascular Health-Progress at Last? Can J Cardiol 2018;34:349-53. [PMID: 29290365 DOI: 10.1016/j.cjca.2017.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
525 Packard CJ. LDL cholesterol: How low to go? Trends Cardiovasc Med 2018;28:348-54. [PMID: 29336946 DOI: 10.1016/j.tcm.2017.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
526 Li SS, Blanco Mejia S, Lytvyn L, Stewart SE, Viguiliouk E, Ha V, de Souza RJ, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL. Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2017;6:e006659. [PMID: 29263032 DOI: 10.1161/JAHA.117.006659] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
527 Allaire J, Vors C, Couture P, Lamarche B. LDL particle number and size and cardiovascular risk: anything new under the sun? Curr Opin Lipidol 2017;28:261-6. [PMID: 28460374 DOI: 10.1097/MOL.0000000000000419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
528 Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol 2018;15:215-29. [DOI: 10.1038/nrcardio.2017.189] [Cited by in Crossref: 384] [Cited by in F6Publishing: 403] [Article Influence: 76.8] [Reference Citation Analysis]
529 Afshar M, Thanassoulis G. Lipoprotein(a): new insights from modern genomics. Curr Opin Lipidol 2017;28:170-6. [PMID: 28059953 DOI: 10.1097/MOL.0000000000000392] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
530 Appiah D, Capistrant BD. Cardiovascular Disease Risk Assessment in the United States and Low- and Middle-Income Countries Using Predicted Heart/Vascular Age. Sci Rep 2017;7:16673. [PMID: 29192146 DOI: 10.1038/s41598-017-16901-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
531 Wein T, Lindsay MP, Côté R, Foley N, Berlingieri J, Bhogal S, Bourgoin A, Buck BH, Cox J, Davidson D, Dowlatshahi D, Douketis J, Falconer J, Field T, Gioia L, Gubitz G, Habert J, Jaspers S, Lum C, Mcnamara Morse D, Pageau P, Rafay M, Rodgerson A, Semchuk B, Sharma M, Shoamanesh A, Tamayo A, Smitko E, Gladstone DJ. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. International Journal of Stroke 2018;13:420-43. [DOI: 10.1177/1747493017743062] [Cited by in Crossref: 124] [Cited by in F6Publishing: 143] [Article Influence: 24.8] [Reference Citation Analysis]
532 Swartz RH, Ladhani NNN, Foley N, Nerenberg K, Bal S, Barrett J, Bushnell C, Chan WS, Chari R, Dowlatshahi D, Amrani ME, Gandhi S, Gubitz G, Hill MD, James A, Jeerakathil T, Jin A, Kirton A, Lanthier S, Lausman A, Leffert LR, Mandzia J, Menon B, Pikula A, Poppe A, Potts J, Ray J, Saposnik G, Sharma M, Smith EE, Bhogal S, Smitko E, Lindsay MP; Heart and Stroke Foundation Canadian Stroke Best Practice Advisory Committees. Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy. Int J Stroke 2018;13:406-19. [PMID: 29171360 DOI: 10.1177/1747493017743801] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
533 Merchán V. A. Propuesta personal de actualización para el tratamiento de la hipercolesterolemia en Colombia. Revista Colombiana de Cardiología 2017;24:25-31. [DOI: 10.1016/j.rccar.2017.10.002] [Reference Citation Analysis]
534 Adatia F, Galway S, Grubisic M, Lee M, Daniele P, Humphries KH, Sedlak TL. Cardiac Medication Use in Patients with Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease. Journal of Women's Health 2017;26:1185-92. [DOI: 10.1089/jwh.2016.5984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
535 Barry AR, Babadagli HE, Basaraba JE, Boswell R, Chen JW, Omar MA, Pollmann DM, Zhou JS, Ackman ML. Review of the top 5 cardiology studies of 2015-16. Can Pharm J 2017;150:380-386. [DOI: 10.1177/1715163517729835] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
536 Raggi P, Pontone G, Andreini D. Role of new imaging modalities in pursuit of the vulnerable plaque and the vulnerable patient. Int J Cardiol 2018;250:278-83. [PMID: 29102056 DOI: 10.1016/j.ijcard.2017.10.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
537 Arsenault BJ, Bourgeois R, Mathieu P. Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases? Can J Cardiol 2017;33:1513-6. [PMID: 29100654 DOI: 10.1016/j.cjca.2017.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
538 Chami N, Simons JE, Sweetman A, Don-wauchope AC. Rates of inappropriate laboratory test utilization in Ontario. Clinical Biochemistry 2017;50:822-7. [DOI: 10.1016/j.clinbiochem.2017.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
539 Anderson TJ. Importance of Optimization of Cardiovascular Risk Factors and Lifestyle Behaviours. Canadian Journal of Cardiology 2017;33:1221-2. [DOI: 10.1016/j.cjca.2017.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
540 Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. J Am Coll Cardiol 2017;70:1637-46. [PMID: 28935041 DOI: 10.1016/j.jacc.2017.08.006] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 20.0] [Reference Citation Analysis]
541 Ha V, Viguiliouk E, Kendall CWC, Balachandran B, Jenkins DJA, Kavsak PA, Sievenpiper JL. Effect of a low glycemic index diet versus a high-cereal fibre diet on markers of subclinical cardiac injury in healthy individuals with type 2 diabetes mellitus: An exploratory analysis of a randomized dietary trial. Clin Biochem 2017;50:1104-9. [PMID: 28958804 DOI: 10.1016/j.clinbiochem.2017.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
542 Al Hamarneh YN, Tsuyuki RT, Jones CA, Manns B, Tonelli M, Scott-Douglass N, Jindal K, Tink W, Hemmelgarn BR. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial. Am J Kidney Dis 2018;71:42-51. [PMID: 28912054 DOI: 10.1053/j.ajkd.2017.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
543 Grand'Maison S, Pilote L, Schlosser K, Stewart DJ, Okano M, Dayan N. Clinical Features and Outcomes of Acute Coronary Syndrome in Women With Previous Pregnancy Complications. Can J Cardiol 2017;33:1683-92. [PMID: 29173607 DOI: 10.1016/j.cjca.2017.08.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
544 Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation 2017;136:1878-91. [PMID: 28877913 DOI: 10.1161/CIRCULATIONAHA.117.027966] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 21.6] [Reference Citation Analysis]
545 Galway S, Adatia F, Grubisic M, Lee M, Daniele P, Humphries KH, Sedlak TL. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease. Journal of Women's Health 2017;26:976-83. [DOI: 10.1089/jwh.2016.5983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
546 Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, Senatore FF. Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. J Clin Hypertens (Greenwich) 2017;19:1015-24. [PMID: 28856834 DOI: 10.1111/jch.13089] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 17.2] [Reference Citation Analysis]
547 Marinangeli CPF, Foisy S, Shoveller AK, Porter C, Musa-Veloso K, Sievenpiper JL, Jenkins DJA. An Appetite for Modernizing the Regulatory Framework for Protein Content Claims in Canada. Nutrients 2017;9:E921. [PMID: 28832556 DOI: 10.3390/nu9090921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
548 Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evolocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther 2017;17:1447-61. [PMID: 28812389 DOI: 10.1080/14712598.2017.1365134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
549 Zhu YM, Verma S, Fung M, McQueen MJ, Anderson TJ, Lonn EM. Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. Can J Cardiol 2017;33:1305-11. [PMID: 28941609 DOI: 10.1016/j.cjca.2017.08.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
550 Rothe D, Paterson I, Cox-kennett N, Gyenes G, Pituskin E. Prevention of Cardiovascular Disease Among Cancer Survivors: the Role of Pre-existing Risk Factors and Cancer Treatments. Curr Epidemiol Rep 2017;4:239-47. [DOI: 10.1007/s40471-017-0117-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
551 Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag 2017;13:293-303. [PMID: 28831263 DOI: 10.2147/VHRM.S108874] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
552 Cartier L, Collins C, Lagacé M, Douville P. The Effect of Triglyceride Concentration on Attainment of Lipid Targets in Patients with Diabetes. Canadian Journal of Diabetes 2017;41:380-4. [DOI: 10.1016/j.jcjd.2016.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
553 Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol 2017;69:692-711. [PMID: 28183512 DOI: 10.1016/j.jacc.2016.11.042] [Cited by in Crossref: 460] [Cited by in F6Publishing: 386] [Article Influence: 92.0] [Reference Citation Analysis]
554 Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. Clin Lymphoma Myeloma Leuk 2017;17:870-878.e1. [PMID: 28803825 DOI: 10.1016/j.clml.2017.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
555 Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS. The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. Arq Bras Cardiol 2017;108:518-25. [PMID: 28699975 DOI: 10.5935/abc.20170089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
556 Turgeon RD, Anderson TJ, Grégoire J, Pearson GJ. 2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. Can Pharm J (Ott) 2017;150:243-50. [PMID: 29163725 DOI: 10.1177/1715163517713031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
557 Klop B, Hartong SCC, Vermeer HJ, Schoofs MWCJ, Kofflard MJM. Risk of misclassification with a non-fasting lipid profile in secondary cardiovascular prevention. Clin Chim Acta 2017;472:90-5. [PMID: 28689857 DOI: 10.1016/j.cca.2017.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
558 Mehdar A, Hegele RA, Kim RB, Gryn SE. Statin therapy: time for a precision medicine approach? Expert Review of Precision Medicine and Drug Development 2017;2:187-92. [DOI: 10.1080/23808993.2017.1356685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
559 Gaudet D, Drouin-chartier J, Couture P. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Canadian Journal of Cardiology 2017;33:872-82. [DOI: 10.1016/j.cjca.2016.12.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
560 Wong CJ, Inouye L. What's in a Number? Risk Thresholds in Different Statin Guidelines. J Gen Intern Med 2017;32:1071-3. [PMID: 28664259 DOI: 10.1007/s11606-017-4114-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
561 Mancini GBJ, Gupta M, Tsigoulis M, Cannon CP, Genest J, Ray KK, Santos RD, Watts GF, Raggi P. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis 2017;263:112-8. [PMID: 28623740 DOI: 10.1016/j.atherosclerosis.2017.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
562 Meneilly GS, Berard LD, Cheng AYY, Lin PJ, MacCallum L, Tsuyuki RT, Yale JF, Nasseri N, Richard JF, Goldin L, Langer A, Tan MK, Leiter LA. Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. Can J Diabetes 2018;42:23-30. [PMID: 28583470 DOI: 10.1016/j.jcjd.2017.03.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
563 Karasek D, Vaverkova H, Cibickova L, Gajdova J, Kubickova V. Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness. J Clin Lipidol 2017;11:442-9. [PMID: 28502501 DOI: 10.1016/j.jacl.2017.01.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
564 Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation 2017;135:1819-31. [DOI: 10.1161/circulationaha.116.025233] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
565 Naugler C, Cook C, Morrin L, Wesenberg J, Venner AA, Campbell N, Anderson T. Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores: A Quality-Improvement Initiative. Canadian Journal of Cardiology 2017;33:682-4. [DOI: 10.1016/j.cjca.2017.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
566 Spence JD. Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention. Canadian Journal of Cardiology 2017;33:626-34. [DOI: 10.1016/j.cjca.2017.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
567 Rabi DM. The Evolution of Targeted Interventions in the Age of Precision Medicine. Can J Cardiol 2017;33:597-600. [PMID: 28449832 DOI: 10.1016/j.cjca.2017.03.004] [Reference Citation Analysis]
568 Rouleau CR, Toivonen K, Aggarwal S, Arena R, Campbell TS. The association between insomnia symptoms and cardiovascular risk factors in patients who complete outpatient cardiac rehabilitation. Sleep Medicine 2017;32:201-7. [DOI: 10.1016/j.sleep.2017.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
569 Choi HY, Hafiane A, Schwertani A, Genest J. High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Canadian Journal of Cardiology 2017;33:325-33. [DOI: 10.1016/j.cjca.2016.09.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
570 Genest J. Familial Hypercholesterolemia: Awareness, Appraisal, and Action. Canadian Journal of Cardiology 2017;33:298-9. [DOI: 10.1016/j.cjca.2016.09.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
571 Anderson TJ. Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go? Canadian Journal of Cardiology 2017;33:405-8. [DOI: 10.1016/j.cjca.2016.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
572 Wang LR, Hegele RA. Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology 2017;33:334-42. [DOI: 10.1016/j.cjca.2016.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
573 Nordestgaard BG, Langlois MR. Precision of nonfasting lipid profiles should focus on clinical relevance rather than necessarily obtaining the least variation. Clinical Chemistry and Laboratory Medicine (CCLM) 2017;55. [DOI: 10.1515/cclm-2016-1104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
574 Angelino D, Cossu M, Marti A, Zanoletti M, Chiavaroli L, Brighenti F, Del Rio D, Martini D. Bioaccessibility and bioavailability of phenolic compounds in bread: a review. Food Funct 2017;8:2368-93. [DOI: 10.1039/c7fo00574a] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
575 Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 2017;18:29-40. [DOI: 10.1007/s11154-016-9402-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 72] [Article Influence: 14.8] [Reference Citation Analysis]
576 Teo KK, Dokainish H. Effective Management of Cardiovascular Risk Factors-Are We Doing Enough? Can J Cardiol 2017;33:300-2. [PMID: 27956041 DOI: 10.1016/j.cjca.2016.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
577 Otto CM. Statins for primary prevention of cardiovascular disease : Patients need better tools to navigate divergent recommendations. Heart 2017;103:477-8. [PMID: 27940966 DOI: 10.1136/heartjnl-2016-310959] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
578 Ma I, Viczko J, Naugler C. Proportion of adults fasting for lipid testing relative to guideline changes in Alberta. Clin Biochem 2017;50:344-6. [PMID: 27919599 DOI: 10.1016/j.clinbiochem.2016.11.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
579 Anderson TJ. Bringing Structure to the Art of Lipid-Lowering Therapy. Journal of the American College of Cardiology 2016;68:2422-2424. [DOI: 10.1016/j.jacc.2016.09.929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
580 Scattolini V, Luni C, Zambon A, Galvanin S, Gagliano O, Ciubotaru CD, Avogaro A, Mammano F, Elvassore N, Fadini GP. Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. Diabetes Ther 2016;7:679-93. [PMID: 27830474 DOI: 10.1007/s13300-016-0210-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
581 Dafoe WA, Hegele RA. Seeking ‘meta guidelines’ for lipids. Eur J Prev Cardiolog 2017;24:72-5. [DOI: 10.1177/2047487316677115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
582 Waters DD, Boekholdt SM. An Evidence-Based Guide to Cholesterol-Lowering Guidelines. Can J Cardiol 2017;33:343-9. [PMID: 28034582 DOI: 10.1016/j.cjca.2016.10.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]